In
light of the ongoing spread of COVID-19, including the global
emergence of new variants, government and public health authorities
continue to recommend measures, and companies otherwise are taking
voluntary efforts as preventative measures, to attempt to contain
and mitigate the effects of the virus. Current efforts include
social distancing, travel restrictions, shutdowns, quarantine
requirements, restrictions on trade, as well as other measures
directed at or impacting businesses. In response to these measures,
we have made certain adjustments to our operations as we continue
to provide our offerings to current and prospective customers. For
example, we continue to employ a hybrid remote-work arrangement by
permitting the majority of our employees to work remotely while
maintaining a limited onsite presence in our offices
worldwide.
As a
preventative measure to mitigate uncertainties associated with
COVID-19, we have continued to take certain cost reduction
measures, including shifting our customer events to virtual-only
platforms, which resulted in realized savings in fiscal years 2020
and 2021 as a result of our placing restrictions on travel and
limiting in-person events.
While
during the beginning stages of the COVID-19 pandemic we experienced
a slow-down in our business, resulting in decreased revenues for
fiscal year 2020 as compared to fiscal year 2019, we experienced
signs of recovery starting in the second half of fiscal year 2020
and continuing through fiscal year 2021. For the year ended
December 31, 2021, we experienced moderate growth, with an increase
in revenue of 10% as compared to fiscal year 2020. However, we
cannot estimate if the signs of recovery will continue or were
temporary (in which case we may go back to experiencing a slowdown
in our business).
As
the COVID-19 pandemic has caused more organizations to shift to a
remote workforce, we believe the value and scalability of our
security management products and services have become even more
appealing to customers who seek to operate safely and for the
long-term in a virtual world. In particular, as has proven evident
over the last fiscal year, we have experienced an increased desire
by organizations to protect their networks and achieve regulatory
compliance. Companies around the world now have employees working
remotely from potentially vulnerable home networks,
accessingcritical
on-premises data stores and infrastructure through VPNs and sharing
information on cloud environments. As these remote working
conditions have created and continue to create vulnerable
conditions for cyberattacks, we aim to continue developing and
marketing our products and solutions to help protect data and
infrastructure against attackers. Further, we believe that
enterprises understand that a data-centric approach to security is
critical and that these elevated risks are expected to remain in
the long-term
We
continue to monitor, assess and respond to the implications of the
COVID-19 pandemic on our operations and our customers, partners and
suppliers. In addition, we continue to actively evaluate and
respond to new developments relating to the evolving COVID-19
pandemic, which has and is expected to result in continued
significant global, social and business disruptions.
We recognize revenues associated
with professional services as we perform the services. As a
percentage of total revenues, we expect our maintenance and
professional services revenues to vary from quarter to quarter
based on fluctuations in license sales, maintenance renewal rates,
professional services attach rates and cyclical factors. The
increase in maintenance is attributable to the growth in our
software license sales to new and existing customers.
See Note 2 to our consolidated
financial statements “Significant Accounting Policies—Revenue
recognition” for more information.
Gross profit is total revenues less
total cost of revenues. Gross margin is gross profit expressed as a
percentage of total revenues. Our gross margin fluctuates from
quarter-to-quarter based on the total revenue amount for the
quarter, the mix of product revenues and maintenance and
professional services revenues. We expect our gross margins to
continue to fluctuate.
Our operating expenses consist of
research and development expenses, sales and marketing expenses and
general and administrative expenses. For each category, personnel
costs are the most significant component of our operating expenses.
Personnel costs consist of salaries and employee benefits
(including vacation expenses, bonuses and share-based
compensation). Sales commissions account for a significant portion
of our sales and marketing compensation costs.
Financial income (expense), net,
consists primarily of bank charges, interest earned on our cash,
cash equivalents restricted bank deposits and marketable
securities, amortization of premium or accretion of discount on our
marketable securities and foreign currency exchange fluctuations.
Foreign currency exchange fluctuations reflect gains or losses
related to transactions denominated in currencies other than the
U.S. dollar, particularly the NIS, the Euro and the GBP. As a
result of our global presence, we expect to continue to incur
expenses in currencies other than the U.S. dollar. As such, we
expect our exposure to fluctuations in foreign currencies to
continue.
The standard corporate tax rate in
Israel for 2021 and thereafter was 23%. We have net operating loss
carry forwards. As of December 31, 2021, our net operating loss
carry forwards for Israeli tax purposes amounted to approximately
$110 million. Under Israeli law, net operating losses can be
carried forward indefinitely and offset against certain future
taxable income. We expect that if or when we become profitable, we
will generate the substantial majority of our taxable income in
Israel. However, no tax benefit was recorded for the years ended
December 31, 2020 and 2021 for the deferred tax assets of the
Israeli entity, since we have recorded a full valuation allowance
against these deferred tax assets which are less likely than not to
be realized.
In addition, we are entitled to tax
benefits under the Investment Law in Israel in respect of our
status as a Benefited Enterprise. Under the Investment Law, our
effective tax rate to be paid with respect to our Israeli taxable
income as a Benefited Enterprise may be lower than the standard
corporate tax rate. The tax benefit period for the Benefited
Enterprise program under the Investment Law is expected to end in
2022. The availability of these tax benefits is subject to certain
requirements, including making specified investments in property
and equipment, and financing a percentage of investments with share
capital. If we do not meet these requirements in the future, the
tax benefits may be canceled and we could be required to refund any
tax benefits that we have already received.
The following tables summarize our
results of operations in dollars and as a percentage of our total
revenues for the periods indicated. The period-to-period comparison
of results is not necessarily indicative of results for future
periods.
Application of
Critical Accounting Policies and Estimates
Our consolidated financial
statements have been prepared in accordance with GAAP. The
preparation of these consolidated financial statements requires us
to make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenue, expenses, and related disclosures.
We base our estimates on historical experience and on various other
assumptions that we believe are reasonable under the circumstances.
We evaluate our estimates and assumptions on an ongoing basis.
Actual results may differ from these estimates. To the extent that
there are material differences between these estimates and our
actual results, our future financial statements will be
affected.
The critical accounting policies
requiring estimates, assumptions, and judgments that we believe
have the most significant impact on our consolidated financial
statements are described below.
Revenue
Recognition
We determine the appropriate revenue
recognition for our contracts with customers by analyzing the type,
terms and conditions of each contract. We classify the revenue
components as products according to the attributes of the
underlying components.
We sell our on-premises software
licenses through both perpetual and term-based license agreements.
Our products offer the same functionality whether our customers
receive them through a perpetual or term-based license. We deliver
our software licenses electronically. Electronic delivery occurs
when we provide the channel partner or customer with access to our
software and license key via a secure portal. We generally
recognize revenues from on-premises software licenses upfront when
we make the software available to the channel partner or, if we are
selling directly, customer. We recognize hardware sales upon
delivery.
We generally recognize revenues from
software sold through term-based license agreements upfront, upon
delivery to the channel partner or, if we are selling directly,
customer. We defer the associated maintenance revenues and
recognize them over the contract period. Assuming we expect to
recover the costs, we capitalize all incremental costs we incur to
obtain a contract with a customer that we would not have incurred
if we had not obtained the contract. We include amortization
expense in sales and marketing expenses in our consolidated
statements of operations. We amortize costs incurred in obtaining a
contract as a sales and marketing expense on a straight-line basis
over the expected period of benefit. We periodically review these
costs for impairment.
Our contract payment terms typically
range between 30 and 120 days. We assess collectability based on
several factors, including collection history.
Our contracts with customers for
software licenses include maintenance and may also include training
and/or professional services. Maintenance consists of fees for
providing software updates and technical support for our products
for a specified term. We recognize maintenance revenues ratably
over the contractual service period. We bill for professional
services on a fixed fee basis and recognize revenues as we perform
the services. We defer payments received in advance of services
performed and recognize such payments when we perform the related
services.
In contracts with multiple
performance obligations, we account for individual performance
obligations separately if they are distinct. We allocate the
transaction price to each performance obligation based on its
relative standalone selling price out of the total consideration of
the contract. For maintenance and support contracts, we determine
the standalone selling price based on the price at which we
separately sell a renewal contract. We determine the standalone
selling price for sales of licenses using the residual approach.
For professional services, we determine the standalone selling
prices based on the price at which we separately sell those
services.
Share-Based Compensation
We measure and recognize share-based
compensation expense in our consolidated financial statements based
on the grant date fair value of the award. We recognize the grant
date fair value of the award as an expense based on the graded
vesting attribution method over the requisite service period
(primarily a four-year period).
We estimated the grant date fair
value of share options for the years ended December 31, 2019 and
2020 using the Black-Scholes option-pricing model. Our use of the
Black-Scholes option-pricing model requires the input of highly
subjective assumptions, including estimated fair value of our
ordinary share price, expected share price volatility and expected
term. The fair value of restricted stock units ("RSU") is based on
the closing market value of the underlying shares at the date of
grant.
Following our initial public
offering on April 11, 2019, our ordinary shares are publicly
traded, and therefore we currently base the value of our ordinary
shares on their market price.
|
•
|
Risk-Free Interest Rate. We
base the risk-free interest rate on the implied yield on currently
available U.S. treasury zero-coupon securities with a remaining
term equal to the expected life of our options.
|
|
•
|
Dividend Yield. We base
dividend yield on our historical experience and expectation of no
future dividend payouts. We have historically not paid cash
dividends and have no foreseeable plans to pay cash dividends in
the future.
|
|
•
|
Expected Volatility. We
base expected share price volatility on the historical volatility
of the ordinary shares of comparable companies that are publicly
traded, as well as the historical volatility of the Company’s
ordinary shares.
|
|
•
|
Expected Term. The expected
term of options granted represents the period of time that options
granted are expected to be outstanding. The expected option term is
calculated using the simplified method, as we concluded that
currently our historical share option exercise experience does not
provide an adequate basis to estimate our expected option
term.
|
Any changes in these highly
subjective assumptions would significantly impact our share-based
compensation expense.
Income
Taxes
We account for income taxes using
the asset and liability approach, which requires the recognition of
taxes payable or refundable for the current year and the deferred
tax liabilities and assets for the future tax consequences of
events that we have recognized in our financial statements or tax
returns.
We measure current and deferred tax
liabilities and assets based on provisions of the relevant tax law.
We reduce the measurement of deferred tax assets, if necessary, by
the amount of any tax benefits that we do not expect to realize. We
classify interest and penalties relating to uncertain tax positions
within taxes on income.
Accounts
Receivable
We present accounts receivable in
our consolidated balance sheets net of allowance for credit losses
for potential uncollectible amounts. We estimate the collectability
of accounts receivable balances and adjust the allowance for credit
losses based on our assessment of collectability by reviewing
accounts receivable on an aggregated basis where similar
characteristics exist and on an individual basis when it identifies
specific customers with known disputes or collectability issues. We
also consider a number of factors to assess collectability,
including the past due status, creditworthiness of the specific
customer, payment history and reasonable and supportable forecasts
of future economic conditions.
When revenue recognition criteria
are not met for a sale transaction that has been billed, we do not
recognize deferred revenues on our balance sheet or the related
account receivable.
Derivative Instruments
We carry out transactions involving
foreign currency exchange derivative financial instruments. These
transactions are designed to hedge our exposure in currencies other
than the U.S. dollar, and are not designated as an accounting
hedge. We are primarily exposed to foreign exchange risk with
respect to recognized assets and liabilities and anticipated
transactions denominated in the NIS, Euro and British Pound,
including payroll expenses. Going forward we may consider to
designate transactions involving foreign currency exchange
derivative financial instruments as an accounting hedge.
New and
Revised Financial Accounting Standards
Under the JOBS Act, we meet the
definition of an “emerging growth company.” As such, we may avail
ourselves of an extended transition period for complying with new
or revised accounting standards. However, we have chosen to “opt
out” of such extended transition period, and as a result, we will
comply with new or revised accounting standards on the relevant
dates on which adoption of such standards is required for
non-emerging growth companies. Our decision to opt out of the
extended transition period for complying with new or revised
accounting standards is irrevocable.
|
B. |
Liquidity and Capital
Resources
|
As of December 31, 2021, we had
$89.4 million of cash and cash equivalents, restricted bank
deposits, short-term marketable securities and long-term marketable
securities, compared to $104.0 million as of December 31, 2020. The
majority of our cash and cash equivalents, restricted bank deposits
and marketable securities are held in banks in Israel and the
United States. Our marketable securities primarily consist of
highly-rated corporate debt securities and U.S. government agency
securities. We believe that our existing cash and cash equivalents,
restricted bank deposits, short-term marketable securities and
long-term marketable securities will be sufficient to fund our
operations, as well as our working capital and capital expenditures
needs for at least the next 12 months. Our future capital
requirements will depend on many factors, including our rate of
revenue growth, which may be impacted, among other factors, by our
transition to term-based subscription license business model, the
expansion of our sales and marketing activities, the timing and
extent of spending to support product development efforts and
expansion into new geographic locations, the timing of
introductions of new products and enhancements to existing products
and the continuing market acceptance of our products and services.
For information on our future operating lease obligations,
including beyond the next 12 months, see Note 7 to our consolidated
financial statements included elsewhere in this annual
report.
For discussion related to our
financial condition for the year ended December 31, 2019, refer to
Part I, Item 5. “Operating and Financial Review and Prospects” in
our annual report on Form 20-F for the fiscal year ended December
31, 2020, which was originally filed with the SEC on March 2, 2021,
and subsequently by amendment on March 8, 2021.
Net Cash
Used in Operating Activities
Cash used by operating activities
was $14.2 million for the year ended December 31, 2021. This was
primarily due to an increased net loss of $36.9 million adjusted by
non-cash charges of $16.3 million, primarily relating to
share-based compensation of $13.9 million and depreciation expense
of $1.9 million, as well as a favorable impact of $6.4 million
resulting from the net changes in our operating assets and
liabilities. Changes in operating assets and liabilities included
(i) a $9.4 million increase in deferred revenues representing
unearned amounts resulting primarily from increased maintenance and
support sales and (ii) a $3.6 million increase in employee
and payroll accrued expenses offset by (a) a $2.2 million increase
in prepaid expenses and other current assets, (b) a $2.5 million
increase in accounts receivables and (c) a $2.3 million increase in
deferred costs.
Cash used by operating activities
was $17.4 million for the year ended December 31, 2020. This was
primarily due to an increased net loss of $35.4 million adjusted by
non-cash charges of $15.6 million, primarily relating to
share-based compensation of $15.0 million and depreciation expense,
as well as a favorable impact of $2.4 million resulting from the
net changes in our operating assets and liabilities. Changes in
operating assets and liabilities included (i) a $2.2 million
increase in deferred revenues representing unearned amounts
resulting primarily from increased maintenance and support sales
and (ii) a $4.3 million increase in employee and payroll accrued
expenses and operating lease liabilities, net, partially offset by
(a) a $2.6 million increase in deferred taxes and other non-current
assets, (b) a $0.5 million increase in accounts receivables and (c)
a $0.7 million decrease in trade payables and other accounts
payables.
Net Cash
Used in Investing Activities
Investing activities for the year
ended December 31, 2021 have consisted primarily of investment in
capital expenditures to purchase property and equipment.
During the year ended December 31,
2021, net cash used in investing activities was $1.5 million was
attributable to purchase of capital expenditures to purchase
property and equipment of $1.7 million, partially offset by net
proceeds of marketable securities of $0.2 million.
During the year ended December 31,
2020, net cash used in investing activities was $44.4 million was
attributable to net purchases of marketable securities of $42.3
million and $2.1 million purchase of capital expenditures to
purchase property and equipment for our leased offices.
Net Cash
Provided by Financing Activities
Net cash provided by financing
activities was $1.9 million in the year ended December 31, 2021,
consisting of $2.4 million in proceeds from the exercise of
employee share options, partially offset by the changes in its
related withholding amounts.
Net cash provided by financing
activities was $0.7 million in the year ended December 31, 2020,
consisting of $1.4 million in proceeds from the exercise of
employee share options, partially offset by the changes in its
related withholding amounts.
C.
Research and Development, Patents and Licenses,
etc.
We conduct our research and
development activities primarily in Israel. As of December 31, 2021
our research and development personnel included 181 employees and
contractors.
For a description of our research
and development policies, see “Item 4.B. Business Overview—Research
and development.”
D. Trend Information
Other than as disclosed elsewhere in
this annual report, we are not aware of any trends, uncertainties,
demands, commitments or events for the period from January 1, 2021
to December 31, 2021 that are reasonably likely to have a material
adverse effect on our net revenue, income, profitability, liquidity
or capital resources, or that caused the disclosed financial
information to be not necessarily indicative of future operating
results or financial condition.
|
E. |
Critical Accounting Estimates
|
See “Application of Critical
Accounting Policies and Estimates” in “Item 5.A. Operating Review
and Financial Prospects—Operating results.”
ITEM
6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
|
A. |
Directors and Senior
Management
|
The following table sets forth the
name, age and position of each of our executive officers and
directors:
Name
|
|
Age
|
|
Position
|
Executive Officers
|
|
|
|
|
Reuven
Kitov
|
|
48
|
|
Chief Executive
Officer, Co-Founder and Chairman of the Board
|
Reuven
Harrison
|
|
52
|
|
Chief
Technology Officer, Co-Founder and Director
|
Jack
Wakileh
|
|
50
|
|
Chief Financial
Officer
|
Yoram
Gronich
|
|
53
|
|
Senior Vice
President of Products and Engineering
|
Shay
Dayan
|
|
40
|
|
Vice President
of Research and Development
|
Raymond
Brancato
|
|
57
|
|
Chief Revenue
Officer
|
|
|
|
|
|
|
|
|
|
|
Tom Schodorf
(1)(4)
|
|
63
|
|
Lead
Independent Director
|
Ohad
Finkelstein (4)
|
|
61
|
|
Director
|
Yuval Shachar
(3)(4)
|
|
59
|
|
Director
|
Yair Shamir
(3)(4)
|
|
76
|
|
Director
|
Edouard
Cukierman (4)
|
|
57
|
|
Director
|
Peter Campbell
(1)(2)(4)
|
|
57
|
|
Director
|
Dafna Gruber
(1)(2)(3)(4)
|
|
57
|
|
Director
|
Brian Gumbel
(2)(4)
|
|
46
|
|
Director
|
(1)
|
Member of our
audit committee.
|
(2)
|
Member of our
compensation committee.
|
(3)
|
Member of our
nominating and corporate governance committee.
|
(4)
|
Independent
director under NYSE rules.
|
Reuven Kitov is our Chief Executive
Officer, Co-Founder and Chairman of the board of directors, which
positions he has held since co-founding Tufin in January 2005.
Prior to co-founding Tufin, Mr. Kitov held key project management
and development roles at Check Point Software Technologies, Inc.
from 1998 to 2003. Mr. Kitov holds a Bachelor of Science degree in
Computer Science from the University of Maryland in College Park,
Maryland.
Reuven Harrison is our Chief Technology
Officer, Co-Founder and a director, which positions he has held
since co-founding Tufin in January 2005. Prior to co-founding
Tufin, Mr. Harrison held key software developer positions at Check
Point Software Technologies, Inc. from 1999 to 2003, as well as
other key positions at Capsule Tech, Inc. from 1997 to 1999 and ECS
Inc. from 1991 to 1996. Mr. Harrison holds a Bachelor of Arts
degree in Mathematics and Philosophy from Tel Aviv University in
Israel.
Jack Wakileh is our Chief Financial
Officer, which position he has held since July 2013. Prior to
joining Tufin, Mr. Wakileh worked as a financial and business
consultant for various technology companies from 2010 to 2013. He
was a Co-Founder of iSpade Technologies Ltd. and was Chief
Financial Officer from 2008 to 2010, Co-Chief Executive Officer of
LEADIP Systems Ltd. from 2006 to 2007 and Chief Financial Officer
of VCON Telecommunications Ltd. from 1999 to 2005 prior to which he
held the Corporate Controller position. Mr. Wakileh holds a
Bachelor of Arts degree in Accounting and Economics from Tel Aviv
University in Israel and is a Certified Public Accountant.
Yoram Gronich is our Senior Vice
President of Products and Engineering, which position he has held
since September 2021. Before that, he was our Vice President of
Research and Development from September 2008 to September 2021.
Prior to joining Tufin, Mr. Gronich held software management and
engineering positions at Symantec Corporation from 2005 to 2008 and
project management and team leader roles at Check Point Software
Technologies, Inc. from 2002 to 2005. Mr. Gronich holds a Master of
Science degree in Electrical Engineering and a Bachelor of Science
degree in Physics and Computer Science each from Tel Aviv
University in Israel.
Shay Dayan is our Vice President of
Research and Development, which position he has held since
September 2021. Prior to that and since August 2009, Mr. Dayan held
several roles in Tufin’s research and development department,
including Team Leader, Group Manager, Chief Architect, Director of
system architecture and Chief Technology Officer of cloud products.
From August 2006 until August 2009, he was a development Team
Leader at Radware Ltd. Mr. Dayan holds a Bachelor of Science degree
in Computer Science from Tel Aviv University in Israel.
Raymond Brancato joined Tufin in
January 2021 as our Chief Revenue Officer. He joined Tufin from
AnyVision, an artificial intelligence company, where he was Chief
Revenue Officer from March 2019 to January 2021. Prior to
AnyVision, he held senior sales leadership positions over the
course of 10 years with CA Technologies, including Vice President,
Senior Vice President and General Manager of Business Unit Sales.
Prior to that, he was Vice President of Sales, Americas at Kabira
Technologies from April 2007 to March 2009, Director of Sales at
BMC Software from November 2002 to April 2007, and Vice President
of Sales at Remedy from December 2000 to November 2002. He holds a
Bachelor of Science degree in Finance and Management Science from
the University of South Carolina.
Tom
Schodorf has served as a member of our board of
directors since 2019. Mr. Schodorf founded View Consulting LLC,
specializing in advisory services for the technology industry, in
2014. He previously served as Senior Vice President of Sales
and Field Operations of Splunk Inc. (traded on Nasdaq) from October
2009 to March 2014, and prior to that, he held various sales and
executive management positions at BMC Software and IBM. Mr.
Schodorf has also been a director of Quali and Behavox since 2021,
of Egnyte since 2018 where he is a member of the Compensation
Committee, of OutSystems since 2017 where he is also Chairman of
the Compensation Committee, of Rapid7 since 2016 where he is a
member of the Compensation Committee, and of Kaseya since 2014. Mr.
Schodorf holds a Masters of Business Administration degree from the
University of Dayton in Dayton, Ohio and a Bachelor of Science in
Business Administration from the Ohio State University in
Columbus, Ohio.
Ohad Finkelstein has served as a
director since January 2011. Mr. Finkelstein serves as Managing
Partner of Danli Capital, an investment advisory firm that he
founded in 2017. Mr. Finkelstein is the Co-Founding Partner of
Marker LLC, which he founded in 2011. Prior to that, from 2005 to
2011, he led international investment for Venrock, an Israeli
venture capital firm. He served as the Chairman, Chief Executive
Officer and President at Interoute Communications Limited from 1999
to 2003. Mr. Finkelstein holds a Bachelor of Arts degree in
Political Science and International Marketing from the University
of California, Los Angeles.
Yuval Shachar has served as a director
since October 2009. Mr. Shachar is the Executive Chairman and
Co-Founder of Team8, a venture capital firm specializing in
incubation of security companies. Mr. Shachar serves as Founding
Venture Partner of Innovation Endeavors, which he joined at its
inception, previously serving as an investment partner of its
predecessor fund from 2013. Mr. Shachar served as Co-Founding
Partner of Marker LLC and its predecessors from 2011. From 2004 to
2009, he served as General Manager of a Cisco business unit in its
Service Provider group. Prior to that, Mr. Shachar served as
Co-Founder, President and CEO of P-Cube (which was acquired by
Cisco), and co-founded each of Pentacom and Infogear (which were
each acquired by Cisco). From 1995 to 1998, Mr. Shachar served as
Vice President of Research and Development at VocalTec Ltd. (which
completed an IPO on The Nasdaq Stock Market, or Nasdaq, in 1996),
and previously held key engineering and management positions at
National Semiconductors. Mr. Shachar holds a Bachelor of Science
degree in Mathematics and Computer Science from Tel Aviv University
in Israel.
Yair Shamir has served as a director
from 2007 to 2013 and again from October 2018 to present. Mr.
Shamir has been a Founding and Managing Partner of Catalyst
Investments since its establishment from 1999 to 2013 and again
from 2015 to present. Mr. Shamir was elected as a member of the
Israeli Parliament (Knesset) and served as Minister of Agriculture
of the State of Israel from 2013 to 2015. Mr. Shamir served as the
Chairman of the Israeli Road Safety Authorities from September 2018
until November 2020. Prior to that, he served as the Chairman of
Board of N.T.A. – Metropolitan Mass Transit System until August
2018. Mr. Shamir served as the Chairman of Israel’s National Roads
Company from 2011 to 2012. Mr. Shamir served as the Chairman of
Israel Aerospace Industries Ltd. from 2005 until 2011. From 2004 to
2007, Mr. Shamir was the Chairman of Shamir Optical Industry Ltd.
From 2004 to 2005, Mr. Shamir served as the Chairman of EL AL. From
1997 to 2004, Mr. Shamir served as the Chief Executive Officer and
Chairman of VCON Telecommunications Ltd. Mr. Shamir was a board
member of DSP Group Corporation from 2005 to 2013. Mr. Shamir holds
a Bachelor of Science degree in Electronics Engineering from the
Technion, Israel Institute of Technology in Haifa, Israel.
Edouard Cukierman has served as a
director since 2014. Mr. Cukierman has been a Founding and Managing
Partner of Catalyst Investments since its establishment in 1999,
and has served as the Chairman of Cukierman & Co. Investment
House since its establishment. Prior to establishing and managing
Catalyst Investments, Mr. Cukierman was the President and Chief
Executive Officer of Astra Technological Investments, a Venture
Capital Fund established in 1993. Mr. Cukierman serves as a board
member of Dori Media Group. He is also is the Founder of the
GoforIsrael annual conference. Mr. Cukierman served as a Reserve
Officer of the Crisis & Hostage Negotiation Team and IDF
Spokesman Unit. Mr. Cukierman holds a Master of Business
Administration degree from INSEAD University in Fontainebleau,
France and a Bachelor of Science degree from the Technion, Israel
Institute of Technology in Haifa, Israel.
Peter Campbell has served as a director
since 2019 and served as an external director under the Israeli
Companies Law between July 2019 and May 2020. Mr. Campbell served
as Chief Financial Officer of Mimecast Ltd. (traded on Nasdaq) from
2006 to 2019, where he also served as a director from 2007 to 2015.
He previously served as Chief Financial Officer of SR Telecom Inc.,
where he was employed from 2002 to 2006. Prior to that, Mr.
Campbell was an auditor at Ernst & Young LLP in Canada. Mr.
Campbell is currently a director and chairman of the audit
committee of Latch inc. (traded on Nasdaq) and a director and
chairman of the audit committee of Dataiku. Mr. Campbell holds a
Bachelor of Commerce degree and a Graduate Diploma in accounting
from the John Molson School of Business at Concordia University in
Canada, where he also served as a lecturer.
Dafna Gruber has served as a
member of our board of directors since 2019 and served as an
external director, as such term is defined under the Israeli
Companies Law. Ms. Gruber serves as the chief financial officer of
Netafim Ltd., a private company. Prior to that as chief financial
officer in various companies including Aqua security Ltd. Landa
Corporation Ltd. and Clal Industries Ltd. From 2007 until
2015, Ms. Gruber served as the chief financial officer of Nice
Systems Ltd., a public company traded on Nasdaq and TASE. From 1996
until 2007, Ms. Gruber was part of Alvarion Ltd., a public company
traded on Nasdaq and TASE, mostly as chief financial officer. Ms.
Gruber currently serves as an external director or independent
director of several public companies, including Nova Measuring
Instruments Ltd, ICL group Ltd and Cellebrite DI Ltd. Ms.
Gruber is a certified public accountant and holds a Bachelor’s
degree in Accounting and Economics from Tel Aviv University,
Israel.
Brian Gumbel has served as a director
since 2019. Mr. Gumbel currently serves as the Chief Revenue
Officer of Armis Inc. Prior to joining Armis, he served as the
Chief Revenue Officer for Sisense from October 2019 to April 2020.
He previously served as the Senior Vice President of Worldwide
Sales at Forescout Technologies Inc., where he held senior
management positions from October 2015 to October 2019. Previously,
he led sales and operations at Tanium as the Vice President for
Americas East and Canada from February 2014 to October 2015. Prior
to that, he worked at McAfee from 2007 to 2014 ultimately serving
as the Vice President for Americas East and Canada, and at Cisco
from 2000 to 2007 in various sales and leadership positions. Mr.
Gumbel holds a Bachelor of Science degree in Biology from Marist
College in Poughkeepsie, New York.
Compensation of
Directors and Executive Officers
The aggregate compensation expensed,
including share-based compensation and other compensation expensed
by us and our subsidiaries, to our directors and executive officers
with respect to the year ended December 31, 2021, was $8.2 million.
This amount includes approximately $0.4 million set aside or
accrued to provide pension, severance, retirement, or similar
benefits.
The table below sets forth the
compensation paid to our five most highly compensated office
holders (as defined in the Israeli Companies Law and described
under “Board Practices—Disclosure of Compensation of Executive
Officers” below) during or with respect to the year ended December
31, 2021. We refer to the five individuals for whom disclosure is
provided herein as our “Covered Executives.”
For purposes of the table and the
summary below, “compensation” includes base salary, bonuses,
equity-based compensation, retirement or termination payments,
benefits and perquisites such as car, phone and social benefits and
any undertaking to provide such compensation.
Summary
Compensation Table
Information Regarding the Covered Executive(1)
|
|
Name and Principal Position(2)
|
|
Base
Salary
|
|
|
Benefits and Perquisites(3)
|
|
|
Variable Compensation(4)
|
|
|
Equity-Based Compensation(5)
|
|
|
Total
|
|
|
|
Raymond Brancato, Chief Revenue
Officer
|
|
$
|
320,075
|
|
|
$
|
59,485
|
|
|
$
|
351,726
|
|
|
$
|
1,473,151
|
|
|
$
|
2,204,437
|
|
Reuven Kitov, Chief Executive
Officer
|
|
$
|
300,000
|
|
|
$
|
46,297
|
|
|
$
|
288,667
|
|
|
$
|
658,937
|
|
|
$
|
1,293,901
|
|
Jack Wakileh,
Chief Financial Officer
|
|
$
|
289,966
|
|
|
$
|
139,162
|
|
|
$
|
130,322
|
|
|
$
|
460,938
|
|
|
$
|
1,020,388
|
|
Yoram
Gronich, Senior Vice President of Products and Engineering
|
|
$
|
266,362
|
|
|
$
|
124,945
|
|
|
$
|
70,173
|
|
|
$
|
388,992
|
|
|
$
|
850,472
|
|
Reuven Harrison, Chief Technology Officer
|
|
$
|
269,731
|
|
|
$
|
69,711
|
|
|
$
|
84,097
|
|
|
$
|
340,314
|
|
|
$
|
763,853
|
|
(1)
|
In accordance
with Israeli law, all amounts reported in the table are in terms of
cost to our company, as recorded in our financial statements.
|
|
|
(2)
|
All current
executive officers listed in the table are full-time employees.
Cash compensation amounts denominated in currencies other than the
U.S. dollar were converted into U.S. dollars at the average
conversion rate for the year ended December 31, 2021.
|
|
|
(3)
|
Amounts
reported in this column include benefits and perquisites, including
those mandated by applicable law. Such benefits and perquisites may
include, to the extent applicable to each executive, payments,
contributions and/or allocations for savings funds, pension,
severance, vacation, car or car allowance, medical insurances and
benefits, risk insurances (such as life, disability and accident
insurances), convalescence pay, payments for social security, tax
gross-up payments and other benefits and perquisites consistent
with our guidelines.
|
|
|
(4)
|
Amounts
reported in this column refer to Variable Compensation such as
earned commission, incentive and bonus payments as recorded in our
financial statements for the year ended December 31, 2021.
|
|
|
(5)
|
Amounts
reported in this column represent the expense recorded in our
financial statements for the year ended December 31, 2021 with
respect to equity-based compensation. Assumptions and key variables
used in the calculation of such amounts are described in Note 10 to
our audited consolidated financial statements, which are included
in this annual report.
|
Employment
Agreements with Executive Officers
We have entered into written
employment agreements with each of our executive officers. These
agreements provide for notice periods of varying duration for
termination of the agreement by us or by the relevant executive
officer, during which time the executive officer will continue to
receive base salary and benefits. These agreements also contain
customary provisions regarding noncompetition, confidentiality of
information and assignment-of-inventions. However, the
enforceability of the noncompetition provisions may be limited
under applicable law.
Directors’
Service Contracts
There are no arrangements or
understandings between us, on the one hand, and any of our
directors, on the other hand, providing for benefits upon
termination of their employment or service as directors of our
company.
Equity Incentive
Plans
2007
Israeli Share Option Plan
Effective Date
and Shares Reserved.
On October 21, 2007, our board of
directors adopted the 2007 Israeli Share Option Plan(the “2007
Plan”). The 2007 Plan generally allowed us to grant options to our
employees, directors, officers, consultants, advisors and any other
person providing services to us or any of our affiliates. In May
2017, we extended the terms of options held by certain holders
under the 2007 Plan by an additional 10 years. Unless earlier
terminated pursuant to the original terms of the 2007 Plan, all
granted but unexercised options will expire and cease to be
exercisable at 5:00 p.m. Israel time on the 10th
anniversary of the vesting commencement date of such options. We no
longer make awards under the 2007 Plan. As of February 23, 2022,
options to purchase a total of 2,047,600 shares were outstanding
under the 2007 Plan.
Plan Administration. The 2007 Plan may
be administered by our board of directors or a committee thereof.
Subject to Israeli law and our amended and restated articles of
association or any resolution to the contrary by our board of
directors, the administrator is authorized, in its sole and
absolute discretion, to exercise all powers and authorities
specifically granted to it under the 2007 Plan or necessary or
advisable in the administration of the 2007 Plan.
Vesting Terms and Conditions of the
Options. Unless otherwise determined by the administrator,
options under the 2007 Plan vest and become exercisable as follows:
25% of the shares covered by the options vested on the first
anniversary of the vesting commencement date, 1/3 of the remaining
shares vest on each subsequent anniversary of the vesting
commencement date and all options become fully vested by the fourth
anniversary of the vesting commencement date.
Israeli Tax Law. Unless otherwise
determined by the administrator, any underlying shares issued upon
exercise of options (granted through the “capital gains track
through a trustee” in accordance with Section 102(b)(2) of the
Israeli Income Tax Ordinance (New Version), 1961(the “Israeli Tax
Ordinance”), will be held by a trustee until the lapse of the
holding period (as defined in the 2007 Plan), or, subject to a tax
ruling, until the earlier of a merger (as defined in the 2007 Plan)
or an initial public offering. We appointed a trustee to hold the
allocated options and underlying shares issued upon the exercise
off such options in a trust on behalf of each applicable Israeli
grantee. No underlying shares or additional rights we issue to the
trustee will be held for a period longer than 20 years after the
end of the term of the options.
Termination of Employment or Service.
In the event that the employment or service of a grantee terminates
(other than by reason of death, disability retirement or for
cause), all options of such grantee that are vested but unexercised
on the date of the termination may be exercised unless earlier
terminated in accordance with their terms and if not previously
expired, no later than the earlier of (i) 90 days after such
termination and (ii) the term of the option. All other granted
options will expire upon such termination. In the event of a
grantee’s death during employment or service, or in the event of a
grantee’s termination due to retirement or disability, all of the
grantee’s vested but unexercised options will be exercisable until
the earlier of (i) 180 days after the date of termination of
employment and (ii) the term of the option. In the event of a
grantee’s termination for cause, all options, whether vested or
unvested, will expire.
Merger. In the event of a merger
transaction (as defined in the 2007 Plan), the administrator in its
sole discretion, will decide (i) if and how the unvested options
will be canceled, replaced or accelerated, (ii) if and how vested
options will be exercised, replaced and/or sold by us or the
trustee on the behalf of Israeli participants and (iii) how
underlying shares issued upon exercise of the options and held by
the trustee on behalf of Israeli participants will be replaced
and/or sold by the trustee on behalf of the Israeli
participant.
2008
U.S. Stock Plan
Effective Date and Shares Reserved. On
May 25, 2008, our board of directors adopted the 2008 U.S. Stock
Plan(the “2008 Plan”). The 2008 Plan generally allowed us to grant
no statutory share options, incentive share options that satisfied
the requirements of Section 422 of the Code, and the sale or award
of shares to our employees, outside directors and consultants and
those of Tufin Software North America, Inc., as well as any of our
other subsidiaries. We no longer make awards under the 2008 Plan.
As of February 23, 2022, options to purchase a total of 343,658
shares were outstanding under the 2008 Plan.
Plan Administration. The 2008 Plan may
be administered by one or more committees of the board of
directors. The entire board of directors may administer the 2008
Plan if no committee is otherwise appointed. Subject to the
provisions of the 2008 Plan, the board of directors will have full
authority and discretion to take any actions it deems necessary or
advisable for the administration of the 2008 Plan. All decisions,
interpretations and other actions of the board of directors will be
final and binding on all participants.
Terms and Conditions of Awards. Any
shares issued upon exercise of an option or awarded or sold under
the 2008 Plan may be subject to the special forfeiture conditions,
rights of repurchase, rights of first refusal and other transfer
restrictions as the board of directors may determine.
Options. The 2008 Plan requires that
options have an exercise price that is not less than 100% of the
fair market value of a share on the grant date. Incentive share
options granted to an employee owning more than 10% of our or any
of our subsidiaries’ combined voting power will have an exercise
price of at least 110% of the fair market value of the share on the
grant date. The expiration date of an option may be no later than
the 10th anniversary of the date of grant (or the fifth anniversary
in the case of incentive share options granted to employees who, at
the time of grant, own more than 10% of our or any of our
subsidiaries’ combined voting power).
Change in Control. In the event that we
are a party to a merger, consolidation, exchange of shares, sale of
all or substantially all of its assets or like event, all
outstanding options will be subject to the applicable transaction
agreement, which will provide for one or more of the following: (i)
the continuation of our outstanding options (if we are the
surviving corporation); (ii) the assumption of the outstanding
option by the surviving corporation or its parent in a manner that
complies with Section 424(a) of the Code; (iii) the substitution by
the surviving corporation or its parent of new options for the
outstanding options in a manner that complies with Section 424(a)
of the Code; or (iv) the cancelation of the outstanding options
without the payment of any consideration.
2018
U.S. Equity-Based Incentive Plan
Effective Date and Shares Reserved. On
April 9, 2018, our board of directors adopted the 2018 U.S.
Equity-Based Incentive Plan (the “2018 Plan”). The 2018 Plan
generally allowed us to grant options to our employees, directors,
executive officers, consultants, advisors and any other person
providing services to us or any of our affiliates who are U.S.
citizens or who are resident aliens of the United States for U.S.
federal income tax purposes. We no longer make awards under the
2018 Plan. As of February 23, 2022 options to purchase a total of
79,778 shares were outstanding under the 2018 Plan.
Plan Administration. The 2018 Plan may
be administered by a committee of the board of directors. The
entire board of directors may administer the 2018 Plan if no
committee is otherwise appointed. Subject to the provisions of the
2018 Plan, the administrator of the 2018 Plan has full authority
and discretion to take any actions it deems necessary or advisable
for the administration of the 2018 Plan. All decisions,
interpretations and other actions of the administrator of the 2018
Plan will be final and binding on all participants, unless
otherwise determined by the board of directors.
Options. The 2018 Plan allows for the
grant of nonqualified share options and incentive share options
that satisfy the requirements of Section 422 of the Code. Each
award will be evidenced by an option agreement that will govern
such award’s terms and conditions. Only our employees or employees
of our parent or subsidiaries are eligible to receive incentive
share options. The 2018 Plan requires that incentive share options
have an exercise price that is not less than 100% of the fair
market value of a share on the grant date and that nonqualified
share options have an exercise price equal to the fair market value
of a share on the grant date unless the committee administering the
2018 Plan specifies otherwise and the option complies with Section
409A of the Code. Incentive share options granted to an employee
owning more than 10% of our or our and our subsidiaries’ combined
voting power will have an exercise price of at least 110% of the
fair market value of the shares on the grant date. The expiration
date of an option may be no later than the 10th anniversary of the
date of grant, unless otherwise determined by the committee
administering the 2018 Plan (or the fifth anniversary in the case
of incentive share options granted to employees who, at the time of
grant, own more than 10% of our or our parent’s or subsidiaries’
combined voting power).
Termination of Employment or Service.
In the event that the employment or service of a grantee terminates
(other than by reason of death, disability or retirement), all
awards of such grantee that are unvested at the time of such
termination will terminate on the date of such termination, and all
awards of such grantee that are vested and exercisable at the time
of such termination may, unless earlier terminated in accordance
with their terms, be exercised within 12 months after the date of
such termination (or such different period as the committee
administering the 2018 Plan will prescribe). In the event of a
grantee’s death during employment or service or within three months
following such grantee’s termination, or in the event of a
grantee’s termination due to disability, all of the grantee’s
vested awards may be exercised at any time within one year after
such death or disability. In the event of a grantee’s retirement,
all of the grantee’s vested awards, unless earlier terminated in
accordance with their terms, may be exercised at any time within
the three month period following such retirement. If we (or our
affiliate, when applicable) terminate the grantee’s employment or
service for cause, or if at any time during the exercise period,
facts or circumstances arise or are discovered with respect to the
grantee that would have constituted cause, all awards theretofore
granted to such grantee will, to the extent not theretofore
exercised, terminate on the date of such termination (or on such
subsequent date on which such facts or circumstances arise or are
discovered, as the case may be) unless otherwise determined by the
committee administering the 2018 Plan.
Merger or Sale. In the event of a
merger or sale, unless otherwise determined by the committee
administering the 2018 Plan in its sole and absolute discretion,
any award then outstanding will be assumed or will be substituted
by us or by the successor corporation in the merger or sale or by
any affiliate thereof under substantially the same terms as the
award. In the event that awards are not assumed or substituted for
equivalent awards, the committee administering the 2018 Plan may
(i) provide for a grantee to have the right to exercise an award,
or otherwise accelerate vesting of an award, as to all or part of
the shares covered thereby, including shares covered by the award
which would not otherwise be exercisable or vested, and/or (ii)
provide for the cancelation of each outstanding award at the
closing of the merger or sale, and payment to the grantee. In the
event of a merger or sale, the committee administering the 2018
Plan may, without the consent of the grantee, amend, modify or
terminate awards as the committee will deem in good faith to be
appropriate.
2019
Equity-Based Incentive Plan
Effective Date and Shares Reserved. On
February 28, 2019, our board of directors approved our 2019
Equity-Based Incentive Plan(the “2019 Plan”), which became
effective upon shareholder approval on March 21, 2019. Our 2019
Plan replaced our 2007 Plan and our 2018 Plan(the “Prior Plans”),
under which further grants will not be made. The 2019 Plan
generally allows for the grant of options, restricted shares,
restricted share units and other share-based awards to our and our
affiliates’ employees, directors, officers, consultants and
advisors. The 2019 Plan enables us to issue awards under varying
tax regimes, including Section 102 and Section 3(i) awards pursuant
to the Israeli Tax Ordinance and incentive stock options within the
meaning of Section 422 of the Code. The maximum aggregate number of
shares that may be issued pursuant to awards under the 2019 Plan is
the sum of (a) 1,833,333 shares plus (b) on January 1 of each
calendar year during the term of the 2019 Plan commencing in 2020,
a number of shares equal to the lesser of: (i) an amount determined
by our board of directors, if so determined prior to the January 1
of the calendar year in which the increase will occur, (ii) 5% of
the total number of shares outstanding on December 31 of the
immediately preceding calendar year and (iii) 5,000,000
shares.
Additionally, any share (i)
underlying an award under the 2019 Plan or the Prior Plans (in an
amount not to exceed 813,515 shares under the Prior Plans) that has
expired, or was canceled, terminated, forfeited, repurchased or
settled in cash in lieu of issuance of shares, for any reason,
without having been exercised, (ii) tendered to pay the exercise
price of an award (or the exercise price or other purchase price of
any option or other award under the Prior Plans), or withholding
tax obligations with respect to an award (or any awards under the
Prior Plans), or (iii) subject to an award (or any award under the
Prior Plans) that is not delivered to a grantee because such shares
are withheld to pay the exercise price (or of any award under the
Prior Plans), or withholding tax obligations with respect to such
award (or such other award) will automatically be available for
grant under the 2019 Plan. As of February 23, 2022, options to
purchase a total of 2,068,509 shares and 2,453,049
unvested RSUs were outstanding under the 2019 Plan. In addition,
our board of directors approved the grant of 1,679,300 RSUs to
certain of our employees, which grant became effective on March 1,
2022.
Plan Administration. Either our board
of directors or a committee established by our board of directors
administers the 2019 Plan, and such administrator will have full
authority in its discretion to determine (i) eligible grantees,
(ii) grants of awards and setting the terms and provisions of award
agreements (which need not be identical) and any other agreements
or instruments under which awards are made, including the number of
shares underlying each award and the class of shares underlying
each award (if more than one class was designated by our board of
directors), (iii) the time or times at which awards will be
granted, (iv) the terms, conditions and restrictions applicable to
each award (which need not be identical) and any shares acquired
upon the exercise or (if applicable) vesting thereof, (v) to
accelerate, continue, extend or defer the exercisability of any
award or the vesting thereof, including with respect to the period
following a grantee’s termination of employment or other service,
(vi) the interpretation of the 2019 Plan and any award agreement
and the meaning, interpretation and applicability of terms referred
to in applicable laws, (vii) policies, guidelines, rules and
regulations relating to and for carrying out the 2019 Plan, and any
amendment, supplement or rescission thereof, as it may deem
appropriate, (viii) to adopt supplements to, or alternative
versions of, the 2019 Plan, including, without limitation, as it
deems necessary or desirable to comply with the laws of, or to
accommodate the tax regime or custom of, foreign jurisdictions
whose citizens or residents may be granted awards, (ix) the fair
market value of the shares or other property, (x) the tax track
(capital gains, ordinary income track or any other track available
under the Section 102 of the Israeli Tax Ordinance) for the purpose
of Section 102 to the Israeli Tax Ordinance, (xi) the authorization
and approval of conversion, substitution, cancelation or suspension
under and in accordance with the 2019 Plan of any or all awards or
shares, (xii) the amendment, modification, waiver or supplement of
the terms of each outstanding award (with the consent of the
applicable grantee, if such amendments refers to the increase of
the exercise price of awards or reduction of the number of shared
underlying an award (but, in each case, other than as a result of
an adjustment or exercise of rights in accordance with the
provisions of the 2019 Plan) unless otherwise provided under the
terms of the 2019 Plan, (xiii) without limiting the generality of
the foregoing, and subject to the provisions of applicable law, to
grant to a grantee who is the holder of an outstanding award, in
exchange for the cancelation of such award, a new award having an
exercise price lower than that provided in the award so canceled
and containing such other terms and conditions as the committee may
prescribe in accordance with the provisions of the 2019 Plan or to
set a new exercise price for the same award lower than that
previously provided in the award, (xiv) to correct any defect,
supply any omission or reconcile any inconsistency in the 2019 Plan
or any award agreement and all other determinations and take such
other actions with respect to the 2019 Plan or any award as it may
deem advisable to the extent not inconsistent with the provisions
of the 2019 Plan or applicable law, (xv) to designate any of our
officers or other persons to manage the day to day administration
of the awards granted under the 2019 Plan or authorize any of them
to act on behalf of the committee with respect to any matter,
right, obligation, determination or election which is the
responsibility of or which is allocated to the committee herein,
(xvi) to determine that awards, shares issuable upon the exercise
or (if applicable) vesting of awards and/or any securities issued
or distributed with respect thereto, shall be allocated or issued
to, or held by, the representative in trust for the benefit of the
grantees and (xvii) any other matter which is necessary or
desirable for, or incidental to, the administration of the 2019
Plan and any award thereunder. The board of directors and the
committee need not take the same action or determination with
respect to all awards, with respect to certain types of awards,
with respect to all service providers or any certain type of
service providers and actions and determinations may differ as
among the grantees, and as between the grantees and any other
holders of our securities. The board of directors may, at any time,
suspend, terminate, modify, or amend the 2019 Plan, whether
retroactively or prospectively.
Types and Terms and Conditions of
Awards. The committee may grant awards intended to qualify
as an incentive stock option, non-qualified stock option, Section
102 award, Section 3(i) award, or other designations under other
regimes. The 2019 Plan generally requires that incentive stock
options have an exercise price that is not less than 100% of the
fair market value of a share underlying such options or 110% in
case of an employee who at the time of the grant owns shares
possessing more than 10% of the total combined voting power of all
classes of our shares or of any of our subsidiaries on the date of
grant of such options or such other price as may be determined
pursuant to the Code. The exercise price of any other awards
granted will be determined by the committee.
The exercise period of an option
award will be 10 years from the date of grant of the award unless
otherwise determined by the committee, but subject to the vesting
and the early termination provisions, provided that the period of
an incentive stock option granted to an employee who at the time of
the grant owns shares possessing more than 10% of the total
combined voting power of all classes of our shares or of any of our
subsidiaries, shall not exceed five years from the date of grant.
Except as described below, an award generally may not be exercised
unless the grantee is then in our employ or service and unless the
grantee has remained continuously so employed since the date of
grant of the award and throughout the vesting dates. In the event
that the employment or service of a grantee terminates (other than
by reason of death, disability or retirement), unless otherwise
determined by the committee, all awards of such grantee that are
unvested at the time of such termination shall terminate on the
date of such termination, and all awards of such grantee that are
vested and exercisable at the time of such termination may, unless
earlier terminated in accordance with their terms, be exercised
within up to three months after the date of such termination (or
such different period as the committee will prescribe), but in any
event no later than the date of expiration of the award’s term as
set forth in the award agreement or pursuant to this 2019 Plan. In
the event of a grantee’s death during employment or service or
within three months following such grantee’s termination, (or such
longer period as determined by the committee), or in the event of a
grantee’s termination due to disability, all of the grantee’s
vested awards may be exercised at any time within one year after
such death or disability (or such longer period as determined by
the committee). In the event of a grantee’s retirement, all of the
grantee’s vested awards, unless earlier terminated in accordance
with their terms, may be exercised at any time within the three
month period following such retirement (or such different period as
the committee shall prescribe). If we (or our affiliate, when
applicable) terminate the grantee’s employment or service for cause
(as defined in the 2019 Plan), or if at any time during the
exercise period (whether prior to and after termination of
employment or service, and whether or not the grantee’s employment
or service is terminated by either party as a result thereof),
facts or circumstances arise or are discovered with respect to the
grantee that would have constituted cause, all awards theretofore
granted to such grantee (whether vested or not) shall, to the
extent not theretofore exercised, terminate on the date of such
termination (or on such subsequent date on which such facts or
circumstances arise or are discovered, as the case may be) unless
otherwise determined by the committee.
Section 102 of the Israeli Tax
Ordinance allows our employees, directors and executive officers
who are not controlling shareholders and are Israeli residents for
tax purposes to receive favorable tax treatment for share-based
awards. Section 102 includes two alternatives for tax treatment
involving the issuance of awards to a trustee for the benefit of
the grantees and also includes an additional alternative for the
issuance of awards directly to the grantee. We elected the “capital
gain track” pursuant to Section 102(b)(2) of the Israeli Tax
Ordinance for grants to eligible Israeli grantees as provided
above, which may allow favorable tax treatment for such grantees.
In order to comply with the terms of the capital gain track, all
awards granted under the 2019 Plan and subject to the provisions of
Section 102 of the Israeli Tax Ordinance, as well as the shares
issued upon exercise of such awards and any rights granted
thereunder, including bonus shares, must be registered in the name
of a trustee selected by the board and held in trust for the
benefit of the relevant grantee for the requisite period prescribed
by the Israeli Tax Ordinance or such longer period as set by the
committee. The trustee may release these awards or shares to the
holders thereof after the expiration of the required statutory
holding period, provided that the trustee has received an
acknowledgment from the Israeli Tax Authority that the grantee paid
all applicable taxes, or the trustee and/or us and/or our affiliate
withholds all applicable taxes and compulsory payments due. Our
non-employee service providers and controlling shareholders may
only be granted options or RSUs under Section 3(i) of the Israeli
Tax Ordinance, which will be taxed as ordinary income upon the
exercise of such awards into shares.
The administrator may grant
restricted share units, or RSUs, under the 2019 Plan, which are
awards covering a number of shares that are settled, if vested, by
issuance of those shares. The award agreement for any restricted
shares granted will provide the vesting schedule and purchase
price, if any, for the restricted shares. If a grantee’s employment
or services to us or any of our affiliates terminates for any
reason prior to the vesting of such grantee’s restricted shares,
any shares that remain subject to vesting will be forfeited by such
grantee. No payment of exercise price (subject to applicable law
and the terms of the award agreement) will be required as
consideration for RSUs.
The administrator may grant other
awards under the 2019 Plan, including shares (which may, but need
not, be restricted shares), cash, a combination of cash and shares,
awards denominated in share units, and share appreciation rights.
However, to qualify as Section 102 or Section 3(i) awards pursuant
to the Israeli Tax Ordinance, the award must be share-based
compensation only and not cash compensation or any award that is
settled in cash.
Adjustment Provisions. In the event of
a division or subdivision of our outstanding share capital, any
distribution of bonus shares (share split), consolidation or
combination of our share capital (reverse stock split),
reclassification with respect to our shares or any similar
recapitalization events, a merger (including, a reverse merger and
a reverse triangular merger), consolidation, amalgamation or like
transaction of us with or into another corporation, reorganization
(which may include a combination or exchange of shares, spin-off or
other corporate divestiture or division, or other similar
occurrences), the committee shall have the authority to make,
without the need for a consent of any holder of an award, such
adjustments as determined by the committee to be appropriate, in
its discretion, in order to adjust (i) the number and class of
shares reserved and available for grants of awards, (ii) the number
and class of shares covered by outstanding awards, (iii) the
exercise price per share covered by any award, (iv) the terms and
conditions concerning vesting and exercisability and the term and
duration of the outstanding awards and (v) any other terms of the
award that in the opinion of the committee should be
adjusted.
In the event of (i) a sale of all or
substantially all of our assets, or a sale (including an exchange)
of all or substantially all of our shares, to any person, or a
purchase by any of our shareholders or by an affiliate of such
shareholder, of all or substantially all of our shares held by all
or substantially all other shareholders or by other shareholders
who are not affiliated with such acquiring party; (ii) a merger
(including, a reverse merger and a reverse triangular merger),
consolidation, amalgamation or like transaction of us with or into
another corporation; (iii) a scheme of arrangement for the purpose
of effecting such sale, merger, consolidation, amalgamation or
other transaction; (iv) change in board event, which means any time
at which individuals who, as of the effective date of the 2019
Plan, constitute the incumbent board cease for any reason to
constitute at least a majority of the board; provided, however,
that any individual becoming a director subsequent to the effective
date of the 2019 Plan whose election, or nomination for election by
our shareholders, was approved by a vote of at least a majority of
the directors then comprising the incumbent board shall be
considered as though such individual were a member of the incumbent
board, but excluding, for this purpose, any such individual whose
initial assumption of office occurs as a result of an actual or
threatened election contest with respect to the election or removal
of directors or other actual or threatened solicitation of proxies
or consents by or on behalf of a person other than the board; (v)
approval by our shareholders of a complete liquidation or
dissolution of the company; or (vi) such other transaction or set
of circumstances that is determined by the board (being the
incumbent board in case of a change in board event), in its
discretion, to be a transaction subject to these provisions of the
2019 Plan; excluding any of the above transactions in clauses (i)
through (v) if the board (being the incumbent board in case of a
change in board event) determines that such transaction should be
excluded from the definition hereof and the applicability of this
provision of the 2019 Plan, any award then outstanding will be
assumed or will be substituted by us or by the successor
corporation in such change in control or by any affiliate thereof,
as determined by the committee in its discretion, under terms as
determined by the committee or the terms of the 2019 Plan applied
by the successor corporation to such assumed or substituted award,
unless otherwise determined by the sole and absolute discretion of
the committee. Regardless of whether awards are assumed or
substituted the committee may (but will not be obligated to), in
its sole discretion: (a) provide for grantees to have the right to
exercise their awards or otherwise for the acceleration of vesting
of award in respect of all or part of the shares covered by the
awards which would not otherwise be exercisable or vested, under
such terms and conditions as the committee will determine,
including the cancelation of all unexercised awards (whether vested
or unvested) upon or immediately prior to the closing of the change
in control; and/or (b) provide for the cancelation of each
outstanding and unexercised award at or immediately prior to the
closing of the change in control, and payment to the grantees of an
amount in cash, our shares, the acquirer or of a corporation or
other business entity which is a party to the change in control or
other property, as determined by the committee to be fair in the
circumstances, and subject to such terms and conditions as
determined by the committee. Notwithstanding the foregoing, in the
event of change in control, the committee may determine, in its
sole discretion, that upon completion of such change in control,
the terms of any award be otherwise amended, modified or
terminated, as the committee deems in good faith to be
appropriate.
Miscellaneous Provisions. Awards under
the 2019 Plan are not transferable other than by will or by the
laws of descent and distribution or to a grantee’s designated
beneficiary, unless, in the case of awards other than incentive
stock options, otherwise determined by our committee or under the
2019 Plan, and generally expire 10 years following the grant date.
The board of directors may at any time amend, suspend, terminate or
modify the 2019 Plan and the administrator may at any time modify
or amend any award under the 2019 Plan.
Corporate
Governance Practices
Under the Israeli Companies Law,
companies incorporated under the laws of the State of Israel whose
shares are publicly traded, including companies with shares listed
on NYSE, are considered public companies under Israeli law and are
required to comply with various corporate governance requirements
under Israeli law relating to matters such as external directors,
the audit committee, the compensation committee and an internal
auditor. This is the case even though our shares are not listed on
a stock exchange in Israel. Subject to certain exceptions, these
requirements are in addition to the corporate governance
requirements imposed by NYSE rules and other applicable provisions
of U.S. securities laws to which we are subject (as a foreign
private issuer). Under NYSE rules, a foreign private issuer, such
as us, may generally follow its home country rules of corporate
governance in lieu of the comparable NYSE corporate governance
requirements, except for certain matters, including the composition
and responsibilities of the audit committee and the independence of
its members within the meaning of the rules and regulations of the
SEC.
We currently comply with the rules
generally applicable to U.S. domestic companies listed on NYSE. We
may in the future decide to use the foreign private issuer
exemption with respect to certain NYSE corporate governance
requirements.
Board of
Directors and Executive Officers
Under the Israeli Companies Law, our
board of directors determines our policies and supervises the
performance of our chief executive officer. Our board of directors
may exercise all powers and may take all actions that are not
specifically granted to our shareholders or to management. Our
executive officers are responsible for our day-to-day management.
Our executive officers serve at the discretion of our board of
directors, subject to the terms of their respective employment
agreements.
Independent Directors
We comply with NYSE rules, which
require that a majority of our directors are independent. Our board
of directors has determined that all of our directors, other than
Reuven Kitov and Reuven Harrison, qualify as independent under such
rules.
Board
Composition and Election
Under our amended and restated
articles of association, the number of directors on our board of
directors must be no less than six and no more than 10, including
any director appointed by one or both of our founders, or a founder
director, pursuant to the appointment rights described under
“—Appointment Rights.” The minimum and maximum number of directors
may be changed, at any time and from time to time, by a special
vote of the holders of at least 66 2/3% of our outstanding
shares.
Other than any founder director, our
directors are divided into three classes with staggered three-year
terms. Each class of directors consists, as nearly as possible, of
1/3 of the total number of directors constituting the entire board
of directors (other than any founder director). At each annual
general meeting of our shareholders, the election or re-election of
directors following the expiration of the term of office of the
directors of that class of directors is for a term of office that
expires on the third annual general meeting following such election
or re-election, such that at each annual general meeting the term
of office of only one class of directors will expire. Each
director, aside from any founder director, holds office until the
annual general meeting of our shareholders for the year in which
his or her term expires and until his or her successor is duly
appointed, unless the tenure of such director expires earlier
pursuant to the Israeli Companies Law upon the occurrence of
certain events or unless removed from office by a vote of the
holders of at least 66 2/3% of the total voting power of our
shareholders at a general meeting of our shareholders in accordance
with our amended and restated articles of association.
Our directors who are not founder
directors are divided among the three classes as follows:
|
•
|
the Class I directors consist of
Edouard Cukierman, Reuven Harrison and Yuval Shachar, and their
terms will expire at our annual general meeting of shareholders to
be held in 2023;
|
|
•
|
the Class II directors, consist of
Ohad Finkelstein, Reuven Kitov and Brian Gumbel and their terms
will expire at our annual general meeting of shareholders to be
held in 2024; and
|
|
•
|
the Class III directors consist of
Yair Shamir, Tom Schodorf, Dafna Gruber and Peter Campbell and
their terms will expire at our annual general meeting of
shareholders to be held in 2022.
|
External
Directors
Under the Israeli Companies Law,
companies incorporated under the laws of the State of Israel that
are public companies, including companies with shares listed on
NYSE, are required to appoint at least two external
directors.
Pursuant to regulations enacted
under the Israeli Companies Law, the board of directors of a public
company whose shares are listed on certain non-Israeli stock
exchanges, including NYSE, that do not have a controlling
shareholder (as such term is defined in the Israeli Companies Law),
may, subject to certain conditions, elect to “opt-out” of the
requirements of the Israeli Companies Law regarding the election of
external directors and to the composition of the audit committee
and compensation committee, provided that the company complies with
the requirements as to director independence and audit committee
and compensation committee composition applicable to companies that
are incorporated in the jurisdiction in which its stock exchange is
located. In May 2020, our board of directors elected to opt-out of
the Israeli Companies Law requirements to appoint external
directors and related Israeli Companies Law rules concerning the
composition of the audit committee and compensation
committee.
The foregoing exemptions will
continue to be available to us so long as: (i) we do not have a
“controlling shareholder” (as such term is defined under the
Israeli Companies Law), (ii) our shares are traded on a U.S. stock
exchange, including NYSE, and (iii) we comply with NYSE rules
applicable to domestic U.S. companies. If in the future we were to
have a controlling shareholder, we would again be required to
comply with the requirements relating to external directors and
composition of the audit committee and compensation
committee.
Under the Israeli Companies Law, the
term “controlling shareholder” means a shareholder with the ability
to direct the activities of the company, other than by virtue of
being an office holder. A shareholder is presumed to be a
controlling shareholder if the shareholder holds 50% or more of the
voting rights in a company or has the right to appoint the majority
of the directors of the company or its general manager. For the
purpose of approving transactions with controlling shareholders,
the term “controlling shareholder” also includes any shareholder
that holds 25% or more of the voting rights of the company if no
other shareholder holds more than 50% of the voting rights in the
company.
Lead
Independent Director
As approved by our board of
directors, for so long as the same person serves both as our Chief
Executive Officer and Chairman of the Board, the non-executive
board members will select a Lead Independent Director from among
the independent directors of the Board. If at any meeting of the
Board the Lead Independent Director is not present, a majority of
the independent members of the Board present will select an
independent member of the Board to act as Lead Independent Director
for the purpose and duration of such meeting. The authorities and
responsibilities of the Lead Independent Director include, but are
not limited to, the following:
|
•
|
Presiding at all meetings of the Board of Directors at which the
Chairman is not present, including executive sessions of the
independent directors;
|
|
•
|
Serving as a liaison between the Chairman and the independent
directors;
|
|
•
|
Having the authority to recommend that the Board of Directors
retain consultants or advisers that report directly to the Board of
Directors;
|
|
•
|
Approving information sent to the Board of Directors;
|
|
•
|
Approving meeting agendas for the Board of Directors;
|
|
•
|
Approving meeting schedules to assure that there is sufficient time
for discussion of all agenda items;
|
|
•
|
Having the authority to call meetings of the independent directors;
and
|
|
•
|
If requested by major shareholders, ensuring that he is available
for consultation and direct communication.
|
As Mr. Reuven Kitov is currently the
Company’s Co-Founder, Chairman of the Board of Directors and Chief
Executive Officer, the non-executive board members elected Tom
Schodorf to be the Lead Independent Director.
Appointment Rights
Under our amended and restated
articles of association, our founders, Reuven Kitov and Reuven
Harrison, jointly have the right to appoint one director to our
board of directors so long as they each hold voting control over 2%
of our outstanding ordinary shares. Pursuant to an agreement
between them, Reuven Kitov will designate the director to be
appointed in this instance subject to prior consultation with
Reuven Harrison. If only one of the founders holds voting control
over 2% of our outstanding ordinary shares, such founder has the
sole right to appoint one director. The appointment rights of our
founders are suspended if either founder is otherwise serving on
our board of directors. The term of office for a founder director
expires if the appointment rights are suspended or if the founders
or founder, as the case may be, no longer holds the requisite
voting control.
Under our amended and restated
articles of association, our board of directors may appoint new
directors to fill vacancies (whether such vacancy is due to a
director no longer serving or due to the number of directors
serving being less than the maximum required in our amended and
restated articles of association). Our amended and restated
articles of association provide that the term of a director
appointed by our board of directors to fill any vacancy will be for
the remaining term of office of the director(s) whose office(s)
have been vacated. See “Item 6.C. Board Practices—External
Directors” for a description of the exemption from the requirements
under the Israeli Companies Law to appoint external
directors.
Other
Considerations
Under the Israeli Companies Law, the
chief executive officer of a public company may not serve as the
chairman of the board of directors of that company unless approved
by a special majority of shareholders. However, if the roles of
chief executive officer and chairman of the board of directors are
held by the same person and this arrangement was approved by the
company’s shareholders prior to its initial public offering and is
described in the company’s initial public offering prospectus,
shareholder approval is only required upon the lapse of the fifth
anniversary of the initial public offering. Reuven Kitov, our Chief
Executive Officer, also serves as our Chairman of the board of
directors, as was approved by our shareholders in 2019 prior to our
initial public offering. We may, at the conclusion of the five-year
period, and again thereafter, seek further shareholder approval for
the renewal of such dual role for up to an additional three years
at a time.
In addition, under the Israeli
Companies Law, our board of directors must determine the minimum
number of directors who are required to have “accounting and
financial expertise.” Under applicable regulations, a director with
accounting and financial expertise is a director who, by reason of
his or her education, professional experience and skill, possesses
an expertise in and understanding of financial and accounting
matters and financial statements. He or she must be able to
thoroughly comprehend the financial statements of the company and
initiate debate regarding the manner in which financial information
is presented. In determining the number of directors required to
have such expertise, the board of directors must consider, among
other things, the type and size of the company and the scope and
complexity of its operations. Our board of directors has determined
that we require at least one director with the requisite accounting
and financial expertise, and it has determined Dafna Gruber has
such expertise.
There are no familial relationships
among any of our office holders (including directors).
Audit
Committee
Israeli
Companies Law Requirements
Under the Israeli Companies Law, the
board of directors of a public company must appoint an audit
committee comprised of at least three directors. Our audit
committee consists of three independent directors, Tom Schodorf
(Lead Independent Director), Peter Campbell and Dafna Gruber.
Listing
Requirements
Under NYSE corporate governance
requirements, we are required to maintain an audit committee
consisting of at least three independent directors, all of whom are
financially literate and one of whom has accounting or related
financial management expertise.
Our audit committee consists of
Dafna Gruber, Peter Campbell and Tom Schodorf. Peter Campbell
serves as the chairperson of our audit committee. All members of
our audit committee meet the requirements for financial literacy
under the applicable rules and regulations of the SEC and NYSE
corporate governance rules. Our board of directors has determined
in its business judgment that each of Peter Campbell and Dafna
Gruber are audit committee financial experts as defined by the SEC
rules and has the requisite accounting or related financial
management expertise as required by NYSE corporate governance
requirements. Each of Dafna Gruber, Peter Campbell and Tom Schodorf
is “independent” as such term is defined in Rule 10A-3(b)(1) under
the Exchange Act and NYSE corporate governance requirements for
audit committee members.
Approval
of Transactions with Related Parties
The approval of the audit committee
is required to effect specified actions and transactions with
office holders and controlling shareholders and their relatives, or
in which they have a personal interest. See “Item 6.C. Board
Practices—Fiduciary Duties and Approval of Specified Related Party
Transactions and Compensation under Israeli Law.” The audit
committee may not approve an action or a transaction with a
controlling shareholder or with an office holder unless, among
other things, at the time of approval the audit committee meets the
composition requirements under the Israeli Companies Law.
Audit
Committee Role
Our board of directors has adopted
an audit committee charter that sets forth the responsibilities of
the audit committee consistent with the Israeli Companies Law, SEC
rules and NYSE corporate governance requirements, which include,
among other responsibilities:
|
•
|
retaining and terminating our independent auditors, subject to
board of directors and shareholder ratification;
|
|
•
|
overseeing the independence, compensation and performance of the
company’s independent auditors;
|
|
•
|
the appointment, compensation, retention and oversight of any
accounting firm engaged for the purpose of preparing or issuing an
audit report or performing other audit services;
|
|
•
|
pre-approval of audit and non-audit services to be provided by the
independent auditors;
|
|
•
|
reviewing with management and our independent directors our
financial statements prior to their submission to the SEC;
and
|
|
•
|
approval of certain transactions with office holders and
controlling shareholders, as described below, and other related
party transactions.
|
Additionally, under the Israeli
Companies Law, the role of the audit committee includes the
identification of irregularities in our business management, among
other things, by consulting with the internal auditor or our
independent auditors and suggesting an appropriate course of action
to the board of directors. In addition, the audit committee or the
board of directors, as set forth in the articles of association of
the company, is required to approve the yearly or periodic work
plan proposed by the internal auditor. The audit committee is
required to assess the company’s internal audit system and the
performance of its internal auditor. The Israeli Companies Law also
requires that the audit committee assess the scope of the work and
compensation of the company’s external auditor. In addition, the
audit committee is required to determine whether certain related
party actions and transactions are “material” or “extraordinary”
for the purpose of the requisite approval procedures under the
Israeli Companies Law and whether certain transactions with a
controlling shareholder will be subject to a competitive procedure
(regardless of whether such transactions are deemed extraordinary
transactions) and to set forth the approval process for
transactions that are “non-negligible” (meaning, transactions with
a controlling shareholder that are classified by the audit
committee as non-negligible, even though they are not deemed
extraordinary transactions), as well as determining which types of
transactions would require the approval of the audit committee,
optionally based on criteria which may be determined annually in
advance by the audit committee.
The audit committee charter states
that the audit committee is empowered to conduct or authorize
investigations into any matters within its scope of
responsibilities.
Compensation
Committee
Under the Israeli Companies Law, the
board of directors of any public company must appoint a
compensation committee. Our compensation committee consists of
three independent directors, Peter Campbell, Dafna Gruber and Brian
Gumbel. Peter Campbell serves as the chairman of our compensation
committee.
Listing
Requirements
Under SEC and NYSE rules, there are
heightened independence standards for members of the compensation
committee, including a prohibition against the receipt of any
compensation from us other than standard supervisory board member
fees. Although foreign private issuers are not required to meet
this heightened standard or the requirements general for a
compensation committee, our board of directors has determined that
all of our compensation committee members meet this heightened
standard and other independence requirements. Each of Peter
Campbell, Dafna Gruber and Brian Gumbel is “independent” under the
NYSE corporate governance requirements for compensation committee
members.
Compensation Committee Role
Our board of directors has adopted a
compensation committee charter that sets forth the responsibilities
of the compensation committee consistent with the Israeli Companies
Law, SEC rules and NYSE corporate governance requirements, which
include, among other responsibilities:
|
•
|
recommending to the board of directors the compensation policy for
directors and executive officers, and to recommend to the board of
directors once every three years whether the compensation policy
that had been approved should be extended for a period of more than
three years;
|
|
•
|
recommending to the board of directors updates to the compensation
policy, from time to time, and examine its implementation;
|
|
•
|
deciding whether to approve the terms of office and employment of
directors and executive officers that require approval of the
compensation committee;
|
|
•
|
deciding whether the compensation terms of the chief executive
officer, which were determined pursuant to the compensation policy,
will be exempted from approval by the shareholders because such
approval would harm the ability to engage the chief executive
officer; and
|
|
•
|
administering and, where applicable, recommending to our board of
directors regarding the awarding of employee equity grants.
|
Compensation Policy
In general, under the Israeli
Companies Law, a public company must have a compensation policy
approved by the board of directors after receiving and considering
the recommendations of the compensation committee. In addition, the
compensation policy requires the approval of the general meeting of
the shareholders, which approval requires one of the following: (i)
the majority of shareholder votes counted at a general meeting
including the majority of all of the votes of those shareholders
who are non-controlling shareholders and do not have a personal
interest in the approval of the compensation policy, who vote at
the meeting (excluding abstentions) or (ii) the total number of
votes against the proposal among the shareholders mentioned in
clause (i) above does exceed 2% of the voting rights in the
company. However, under special circumstances, the board of
directors may override the shareholders’ decision and approve the
compensation policy despite the objection of the shareholders on
the condition that the compensation committee and then the board of
directors decide, on the basis of detailed arguments and after
discussing again the compensation policy, that approval of the
compensation policy, despite the objection of the meeting of
shareholders, is for the benefit of the company.
If a company that initially offers
its securities to the public adopts a compensation policy in
advance of its initial public offering, and describes it in its
prospectus, as we did in the prospectus for our initial public
offering, then such compensation policy shall be deemed a validly
adopted policy in accordance with the Israeli Companies Law
requirements described above. Furthermore, if the compensation
policy is set in accordance with the aforementioned relief, then it
will remain in effect for term of five years from the date such
company has become a public company.
The compensation policy must be
based on certain considerations, include certain provisions and
needs to reference certain matters as set forth in the Israeli
Companies Law.
The compensation policy must serve
as the basis for decisions concerning the financial terms of
employment or engagement of office holders, including exculpation,
insurance, indemnification or any monetary payment or obligation of
payment in respect of employment or engagement. The compensation
policy must relate to certain factors, including advancement of the
company’s objectives, business plan and long-term strategy, and
creation of appropriate incentives for office holders. It must also
consider, among other things, the company’s risk management, size
and the nature of its operations. The compensation policy must
furthermore consider the following additional factors:
|
•
|
the education, skills, experience, expertise and accomplishments of
the relevant office holder;
|
|
•
|
the office holder’s position, responsibilities and prior
compensation agreements with that office holder;
|
|
•
|
the ratio between the cost of the terms of employment of an office
holder and the cost of the employment of other employees of the
company, including employees employed through contractors who
provide services to the company, in particular the ratio between
such cost, the average and median salary of the employees of the
company, as well as the impact of such disparities on the work
relationships in the company;
|
|
•
|
if the terms of employment include variable components—the
possibility of reducing variable components at the discretion of
the board of directors and the possibility of setting a limit on
the value of non-cash variable equity-based components; and
|
|
•
|
if the terms of employment include severance compensation—the term
of employment or office of the office holder, the terms of his or
her compensation during such period, the company’s performance
during the such period, his or her individual contribution to the
achievement of the company goals and the maximization of its
profits and the circumstances under which he or she is leaving the
company.
|
The compensation policy must also
include:
|
•
|
with regard to variable components:
|
|
•
|
with the exception of office holders who report directly to the
chief executive officer, determining the variable components on
long-term performance basis and on measurable criteria; however,
the company may determine that an immaterial part of the variable
components of the compensation package of an office holder’s shall
be awarded based on non-measurable criteria, if such amount is not
higher than three monthly salaries per annum, while taking into
account such office holder contribution to the company; and
|
|
•
|
the ratio between variable and fixed components, as well as the
limit of the values of variable components at the time of their
grant;
|
|
•
|
a condition under which the office holder will return to the
company, according to conditions to be set forth in the
compensation policy, any amounts paid as part of his or her terms
of employment, if such amounts were paid based on information later
to be discovered to be wrong, and such information was restated in
the company’s financial statements;
|
|
•
|
the minimum holding or vesting period of variable equity-based
components to be set in the terms of office or employment, as
applicable, while taking into consideration long-term incentives;
and
|
|
•
|
a limit to retirement grants.
|
Our compensation policy, which was
adopted and approved on March 21, 2019 and amended on July 29, 2020
and July 15, 2021, is designed to promote retention and motivation
of directors and executive officers, incentivize superior
individual excellence, align the interests of our directors and
executive officers with our long-term performance and provide a
risk management tool. To that end, a portion of an executive
officer compensation package is targeted to reflect our short- and
long-term goals, as well as the executive officer’s individual
performance. On the other hand, our compensation policy includes
measures designed to reduce the executive officer’s incentives to
take excessive risks that may harm us in the long-term, such as
limits on the value of cash bonuses and equity-based compensation,
limitations on the ratio between the variable and the total
compensation of an executive officer and minimum vesting periods
for equity-based compensation.
Our compensation policy also
addresses each of our executive officers’ individual
characteristics (such as his or her respective position, education,
scope of responsibilities and contribution to the attainment of our
goals) as the basis for compensation variation among our executive
officers, and considers the internal ratios between compensation of
our executive officers and directors and other employees. Pursuant
to our compensation policy, the compensation that may be granted to
an executive officer may include: base salary, annual bonuses and
other cash bonuses (such as a signing bonus and special bonuses
with respect to any special achievements, such as outstanding
personal achievement, outstanding personal effort or outstanding
company performance), equity-based compensation, benefits and
retirement and termination of service arrangements. All cash
bonuses are limited to a maximum amount linked to the executive
officer’s base salary. In addition, the total variable compensation
components (cash bonuses and equity-based compensation) may not
exceed 95% of each executive officer’s total compensation package
with respect to any given calendar year.
An annual cash bonus may be awarded
to executive officers upon the attainment of pre-set periodic
objectives determined by the compensation committee and individual
targets. The annual cash bonus, which may be granted to our
executive officers other than our chief executive officer, is based
on performance objectives and a discretionary evaluation of the
executive officer’s overall performance by our chief executive
officer and subject to minimum thresholds. The annual cash bonus
that may be granted to executive officers other than our chief
executive officer may be based entirely on a discretionary
evaluation. Furthermore, the performance objectives are recommended
by our chief executive officer and approved by our compensation
committee (and, if required by law, by our board of
directors).
The performance measurable
objectives of our chief executive officer are determined annually
by our compensation committee and board of directors, and include
the weight to be assigned to each achievement in the overall
evaluation. A less significant portion of the chief executive
officer’s annual cash bonus may be based on a discretionary
evaluation of the chief executive officer’s overall performance by
the compensation committee and the board of directors based on
quantitative and qualitative criteria.
The equity-based compensation under
our compensation policy for our executive officers (including
members of our board of directors) is designed in a manner
consistent with the underlying objectives in determining the base
salary and the annual cash bonus, with its main objectives being to
enhance the alignment between the executive officers’ interests
with our long-term interests and those of our shareholders and to
strengthen the retention and the motivation of executive officers
in the long term. Our compensation policy provides for executive
officer compensation in the form of share options or other
equity-based awards, such as restricted shares and restricted share
units, in accordance with our equity incentive plans then in place.
All equity-based incentives granted to executive officers shall be
subject to vesting periods in order to promote long-term retention
of the executive officers. The equity-based compensation shall be
granted from time to time and be individually determined and
awarded according to the performance, educational background, prior
business experience, qualifications, role and the personal
responsibilities of the executive officer.
In addition, our compensation policy
contains compensation recovery provisions which allows us under
certain conditions to recover bonuses paid in excess, enables our
chief executive officer to approve an immaterial change in the
terms of employment of an executive officer (provided that the
changes of the terms of employment are in accordance our
compensation policy) and allows us to exculpate, indemnify and
insure our executive officers and directors subject to certain
limitations set forth thereto.
Our compensation policy also
provides for compensation to the members of our board of directors
either (i) in accordance with the amounts provided in the Israeli
Companies Regulations (Rules Regarding the Compensation and
Expenses of an External Director) of 2000, as amended by the
Israeli Companies Regulations (Relief for Public Companies Traded
in Stock Exchange Outside of Israel) of 2000, as such regulations
may be amended from time to time, or (ii) in accordance with the
amounts determined in our compensation policy.
Nominating and
Corporate Governance Committee
Our nominating and corporate
governance committee consists of Dafna Gruber, Yuval Shachar and
Yair Shamir. Yuval Shachar serves as the chairperson of our
nominating and corporate governance committee.
Listing
Requirements
Under NYSE corporate governance
requirements, we are required to maintain a nominating and
corporate governance committee composed only of independent
directors, but may opt out as a foreign private issuer. Our board
of directors has determined that all of our nominating and
corporate governance committee members meet such standards. Each of
Dafna Gruber, Yuval Schachar and Yair Shamir is “independent” under
NYSE corporate governance requirements.
Nominating and Corporate Governance Committee Role
Our board of directors has adopted a
nominating and corporate governance committee charter that sets
forth the responsibilities of the nominating and corporate
governance committee consistent with the Israeli Companies Law, SEC
rules and NYSE corporate governance requirements, which include,
among other responsibilities:
|
•
|
supporting and advising our board of directors in selecting
director nominees, consistent with the criteria approved by our
board of directors, who are best able to fulfill the
responsibilities of a director;
|
|
•
|
overseeing the evaluation of our board of directors and our
management; and
|
|
•
|
otherwise taking a leadership role in shaping our corporate
governance establishing and maintaining effective corporate
governance policies and practices, including developing and
recommending to our board of directors a set of corporate
governance guidelines applicable to our company.
|
Internal
Auditor
Under the Israeli Companies Law, the
board of directors of a public company must appoint an internal
auditor based on the recommendation of the audit committee. The
role of the internal auditor is, among other things, to examine
whether a company’s actions comply with applicable law and orderly
business procedure. Under the Israeli Companies Law, the internal
auditor may not be an interested party or an office holder or a
relative of an interested party or of an office holder, nor may the
internal auditor be the company’s independent auditor or the
representative of the same.
An “interested party” is defined in
the Israeli Companies Law as (i) a holder of 5% or more of the
issued share capital or voting power in a company, (ii) any person
or entity who has the right to designate one or more directors or
to designate the chief executive officer of the company or (iii)
any person who serves as a director or as a chief executive officer
of the company.
Chaikin, Cohen, Rubin & Co. has
been appointed as our internal auditor.
Fiduciary Duties
and Approval of Specified Related Party Transactions and
Compensation under Israeli Law
Fiduciary Duties of Office Holders
The Israeli Companies Law imposes a
duty of care and a duty of loyalty on all office holders of a
company. The duty of care requires an office holder to act with the
degree of skill and care with which a reasonable office holder in
the same position would have acted under the same circumstances.
The duty of care includes, among other things, a duty to use
reasonable means, in light of the circumstances, to obtain:
|
•
|
information on the advisability of a given action brought for
his or her approval or performed by virtue of his or her position;
and
|
|
•
|
all other important information pertaining to such action.
|
The duty of loyalty incumbent on an
office holder requires him or her to act in good faith and for the
benefit of the company, and includes, among other things, the duty
to:
|
•
|
refrain from any act involving a conflict of interest between the
performance of his or her duties in the company and his or her
other duties or personal affairs;
|
|
•
|
refrain from any activity that is competitive with the business of
the company;
|
|
•
|
refrain from exploiting any business opportunity of the company for
the purpose of gaining a personal advantage for himself or herself
or others; and
|
|
•
|
disclose to the company any information or documents relating to
the company’s affairs which the office holder received as a result
of his or her position as an office holder.
|
Disclosure of Personal Interests of an Office Holder and Approval
of Certain Transactions
Under the Israeli Companies Law, a
company may approve an act specified above which would otherwise
constitute a breach of the office holder’s fiduciary duty, provided
that the office holder acted in good faith, the act or its approval
does not harm the company, and the office holder discloses to the
company his or her personal interest in the transaction (including
any significant fact or document) a reasonable time before the
approval of such act. Any such approval is subject to the terms of
the Israeli Companies Law, setting forth, among other things, the
appropriate bodies of the company required to provide such
approval, and the methods of obtaining such approval.
The Israeli Companies Law requires
that an office holder promptly disclose to the company any direct
or indirect personal interest that he or she may have and all
related material information or documents known to him or her
relating to any existing or proposed transaction by the company. An
interested office holder’s disclosure must be made promptly and, in
any event, no later than the first meeting of the board of
directors at which the transaction is considered. An office holder
is not obliged to disclose such information if the personal
interest of the office holder derives solely from the personal
interest of his or her relative in a transaction that is not
considered an extraordinary transaction.
If the transaction is an
extraordinary transaction, the office holder must also disclose any
personal interest held by:
|
•
|
the office holder’s relatives (spouse, siblings, parents,
grandparents, descendants, spouse’s descendants and the spouses of
any of these people); or
|
|
•
|
any company in which the office holder or his or her relatives
holds 5% or more of the shares or voting rights, serves as a
director or general manager or has the right to appoint at least
one director or the general manager.
|
Under the Israeli Companies Law,
unless the articles of association of a company provide otherwise,
a transaction with an office holder or with a third party in which
the office holder has a personal interest, which is not an
extraordinary transaction, requires approval by the board of
directors or a committee authorized by the board of directors. Our
amended and restated articles of association provide that such a
transaction, which is not an extraordinary transaction, shall be
approved by the board of directors or a committee of the board of
directors or any other body or person (which has no personal
interest in the transaction) authorized by the board of directors.
If the transaction considered is an extraordinary transaction with
an office holder or third party in which the office holder has a
personal interest, then audit committee approval is required prior
to approval by the board of directors. Under specific
circumstances, shareholder approval may also be required. For the
approval of compensation arrangements with directors and executive
officers, see “Item 6.B. Compensation—Compensation of Directors and
Executive Officers.”
Any persons who have a personal
interest in the approval of a transaction that is brought before a
meeting of the board of directors or the audit committee may not be
present at the meeting or vote on the matter. However, if the
chairman of the board of directors or the chairman of the audit
committee, as applicable, has determined that the presence of an
office holder with a personal interest is required, such office
holder may be present at the meeting for the purpose of presenting
the matter. Notwithstanding the foregoing, a director who has a
personal interest may be present at the meeting of the board of
directors or the audit committee (as applicable) and vote on the
matter if a majority of the members of the board of directors or
the audit committee (as applicable) have a personal interest in the
approval of such transaction. If a majority of the directors at a
board of directors meeting have a personal interest in the
transaction, such transaction also generally requires approval of
the shareholders of the company.
A “personal interest” is defined
under the Israeli Companies Law as the personal interest of a
person in an action or in a transaction of the company, including
the personal interest of such person’s relative or the interest of
any other corporate body in which the person and/or such person’s
relative is a director or general manager, a 5% shareholder or
holds 5% or more of the issued and outstanding share capital of the
company or of its voting rights, or has the right to appoint at
least one director or the general manager, but excluding a personal
interest stemming solely from the fact of holding shares in the
company. A personal interest also includes (i) a personal interest
of a person who votes according to a proxy of another person,
including in the event that the other person has no personal
interest, and (ii) a personal interest of a person who gave a proxy
to another person to vote on his or her behalf regardless of
whether the discretion of how to vote lies with the person
voting.
An “extraordinary transaction” is
defined under the Israeli Companies Law as any of the
following:
|
•
|
a transaction other than in the ordinary course of business;
|
|
•
|
a transaction that is not on market terms; or
|
|
•
|
a transaction that may have a material impact on the company’s
profitability, assets or liabilities.
|
Disclosure of Personal Interests of a Controlling Shareholder and
Approval of Transactions
Pursuant to the Israeli Companies
Law, the disclosure requirements that apply to an office holder
also apply to a controlling shareholder of a public company.
Extraordinary transactions with a controlling shareholder or in
which a controlling shareholder has a personal interest, including
a private placement in which a controlling shareholder has a
personal interest, and the terms of engagement of the company,
directly or indirectly, with a controlling shareholder or a
controlling shareholder’s relative (including through a corporation
controlled by a controlling shareholder), regarding the company’s
receipt of services from the controlling shareholder, and if such
controlling shareholder is also an office holder or employee of the
company, regarding his or her terms of employment, require the
approval of each of (i) the audit committee (or the compensation
committee with respect to the terms of the engagement as an office
holder or employee, including insurance, indemnification and
compensation), (ii) the board of directors and (iii) the
shareholders, in that order. In addition, the shareholder approval
must fulfill one of the following requirements:
|
•
|
a majority of the shares held by shareholders who have no personal
interest in the transaction and are voting at the meeting must be
voted in favor of approving the transaction, excluding abstentions;
or
|
|
•
|
the shares voted by shareholders who have no personal interest in
the transaction who vote against the transaction represent no more
than 2% of the voting rights in the company.
|
Such majority determined in
accordance with the majority requirement described above is
hereinafter referred to as the Compensation Special Majority
Requirement.
Any such transaction for which the
term is more than three years must be approved in the same manner
every three years, unless with respect to certain transactions as
permitted by the Israeli Companies Law, the audit committee has
determined that a longer term is reasonable under the
circumstances. In addition, transactions with a controlling
shareholder or a controlling shareholder’s relative who serves as
an executive officer in a company, directly or indirectly
(including through a corporation under his control), involving the
receipt of services by a company or their compensation can have a
term of five years from the company’s initial public offering under
certain circumstances.
The Israeli Companies Law requires
that every shareholder that participates, in person or by proxy, in
a vote regarding a transaction with a controlling shareholder, must
indicate in advance or in the ballot whether or not that
shareholder has a personal interest in the vote in question.
Failure to so indicate generally results in the invalidation of
that shareholder’s vote.
Disclosure of Compensation of Executive Officers
For so long as we qualify as a
foreign private issuer, we are not required to comply with the
proxy rules applicable to U.S. domestic filers, including the
requirement applicable to emerging growth companies to disclose the
compensation of our chief executive officer and other two most
highly compensated executive officers on an individual, rather than
an aggregate, basis. Nevertheless, regulations promulgated under
the Israeli Companies Law require us to disclose in the proxy
statement for the annual general meeting of our shareholders (or to
include a reference therein to other previously furnished public
disclosure) the annual compensation of our five most highly
compensated executive officers on an individual, rather than an
aggregate, basis. This disclosure will not be as extensive as that
required of a U.S. domestic issuer.
Compensation of Directors and Executive Officers
Directors. Under the Israeli Companies
Law, the compensation of our directors requires the approval of our
compensation committee, the subsequent approval of the board of
directors and, unless exempted under regulations promulgated under
the Israeli Companies Law, the approval of the shareholders at a
general meeting. If the compensation of our directors is
inconsistent with our compensation policy, then, provided that
those provisions that must be included in the compensation policy
according to the Israeli Companies Law have been considered by the
compensation committee and board of directors, and provided that
shareholder approval is obtained by the Compensation Special
Majority Requirement.
Executive Officers (other than the Chief
Executive Officer). The Israeli Companies Law requires the
approval of the compensation of a public company’s executive
officers (other than the chief executive officer) in the following
order: (i) the compensation committee, (ii) the company’s board of
directors and (iii) if such compensation arrangement is
inconsistent with the company’s compensation policy, the company’s
shareholders (the Compensation Special Majority Requirement).
However, if the shareholders of the company do not approve a
compensation arrangement with an executive officer that is
inconsistent with the company’s compensation policy, the
compensation committee and board of directors may override the
shareholders’ decision if each of the compensation committee and
the board of directors provide detailed reasons for their
decision.
Chief Executive Officer. The Israeli
Companies Law requires the approval of the compensation of a public
company’s chief executive officer in the following order: (i) the
company’s compensation committee, (ii) the company’s board of
directors and (iii) the company’s shareholders (the Compensation
Special Majority Requirement). However, if the shareholders of the
company do not approve the compensation arrangement with the chief
executive officer, the compensation committee and board of
directors may override the shareholders’ decision if each of the
compensation committee and the board of directors provide a
detailed report for their decision. The approval of each of the
compensation committee and the board of directors should be in
accordance with the company’s compensation policy; however, in
special circumstances, they may approve compensation terms of a
chief executive officer that are inconsistent with such policy
provided that they have considered those provisions that must be
included in the compensation policy according to the Israeli
Companies Law and that shareholder approval was obtained (by a
special majority vote as discussed above with respect to the
approval of director compensation). In addition, the compensation
committee may waive the shareholder approval requirement with
regards to the approval of the engagement terms of a candidate for
the chief executive officer position, if the compensation committee
determines that the compensation arrangement is consistent with the
company’s compensation policy, and that the chief executive officer
did not have a prior business relationship with the company or a
controlling shareholder of the company and that subjecting the
approval of the engagement to a shareholder vote would impede the
company’s ability to employ the chief executive officer
candidate.
Duties
of Shareholders
Under the Israeli Companies Law, a
shareholder has a duty to refrain from abusing its power in the
company and to act in good faith and in an acceptable manner in
exercising its rights and performing its obligations to the company
and other shareholders, including, among other things, when voting
at meetings of shareholders on the following matters:
|
•
|
an amendment to the articles of association;
|
|
•
|
an increase in the company’s authorized share capital;
|
|
•
|
the approval of related party transactions and acts of office
holders that require shareholder approval.
|
A shareholder also has a general
duty to refrain from discriminating against other
shareholders.
The remedies generally available
upon a breach of contract also apply to a breach of the shareholder
duties mentioned above, and in the event of discrimination against
other shareholders, additional remedies may be available to the
injured shareholder.
In addition, any controlling
shareholder, any shareholder that knows that its vote can determine
the outcome of a shareholder vote and any shareholder that, under a
company’s articles of association, has the power to appoint or
prevent the appointment of an office holder, or any other power
with respect to a company, is under a duty to act with fairness
towards the company. The Israeli Companies Law does not describe
the substance of this duty except to state that the remedies
generally available upon a breach of contract also apply in the
event of a breach of the duty to act with fairness, taking the
shareholder’s position in the company into account.
Approval
of Private Placements
Under the Israeli Companies Law and
the regulations promulgated thereunder, a private placement of
securities of an Israeli public company whose shares are traded
solely outside of Israel does not require approval at a general
meeting of the shareholders of a company; provided however, that in
special circumstances, such as a private placement, which is
intended to obviate the need to conduct a special tender offer or a
private placement which qualifies as a related party transaction,
for which approval at a general meeting of the shareholders of a
company is required. See “Item 10.B. Memorandum and Articles of
Association—Acquisitions under Israeli Law.”
However, we are subject to NYSE
corporate governance requirements relating to private
placements.
Exculpation,
Insurance and Indemnification of Directors and Officers
Under the Israeli Companies Law, a
company may not exculpate an office holder from liability for a
breach of the duty of loyalty. An Israeli company may exculpate an
office holder in advance from liability to the company, in whole or
in part, for damages caused to the company as a result of a breach
of duty of care but only if a provision authorizing such
exculpation is included in its articles of association. Our amended
and restated articles of association include such a provision. The
company may not exculpate in advance a director from liability
arising from a breach of his or her duty of care in connection with
a prohibited dividend or distribution to shareholders.
As permitted under the Israeli
Companies Law, our amended and restated articles of association
provide that we may indemnify an office holder in respect of the
following liabilities, payments and expenses incurred for acts
performed by him or her as an office holder, either in advance of
an event or following an event:
|
•
|
a monetary liability incurred by or imposed on the office holder in
favor of another person pursuant to a court judgment, including
pursuant to a settlement confirmed as judgment or arbitrator’s
decision approved by a competent court. However, if an undertaking
to indemnify an office holder with respect to such liability is
provided in advance, then such an undertaking must be limited to
events which, in the opinion of the board of directors, can be
foreseen based on the company’s activities when the undertaking to
indemnify is given, and to an amount or according to criteria
determined by the board of directors as reasonable under the
circumstances, and such undertaking shall detail the abovementioned
foreseen events and amount or criteria;
|
|
•
|
reasonable litigation expenses, including reasonable attorneys’
fees, which were incurred by the office holder as a result of an
investigation or proceeding filed against the office holder by an
authority authorized to conduct such investigation or proceeding,
provided that such investigation or proceeding was either (i)
concluded without the filing of an indictment against such office
holder and without the imposition on him of any monetary obligation
in lieu of a criminal proceeding, (ii) concluded without the filing
of an indictment against the office holder but with the imposition
of a monetary obligation on the office holder in lieu of criminal
proceedings for an offense that does not require proof of criminal
intent or (iii) in connection with a monetary sanction;
|
|
•
|
reasonable litigation expenses, including attorneys’ fees, incurred
by the office holder or which were imposed on the office holder by
a court (i) in a proceeding instituted against him or her by the
company, on its behalf, or by a third party, (ii) in connection
with criminal indictment of which the office holder was acquitted
or (iii) in a criminal indictment which the office holder was
convicted of an offense that does not require proof of criminal
intent;
|
|
•
|
expenses he or she incurs as a result of administrative proceedings
that may be instituted against him or her under Israeli securities
laws, if applicable, and payments made to injured persons under
specific circumstances thereunder; and
|
|
•
|
any other matter in respect of which it is permitted or will be
permitted under applicable law to indemnify an office holder in the
company.
|
As permitted under the Israeli
Companies Law, our amended and restated articles of association
provide that we may insure an office holder against the following
liabilities incurred for acts performed by him or her as an office
holder:
|
•
|
a breach of the duty of loyalty to the company, provided that the
office holder acted in good faith and had a reasonable basis to
believe that the act would not harm the company;
|
|
•
|
a breach of duty of care to the company or to another person, to
the extent such a breach arises out of the negligent conduct of the
office holder;
|
|
•
|
a monetary liability imposed on the office holder in favor of a
third party;
|
|
•
|
expenses he or she incurs as a result of administrative proceedings
that may be instituted against him or her under the Israeli
securities laws if applicable, and payments made to injured persons
under specific circumstances thereunder; and
|
|
•
|
any other matter in respect of which it is permitted or will be
permitted under applicable law to insure the liability of an office
holder in the company.
|
Under the Israeli Companies Law, a
company may not indemnify, exculpate or insure an office holder
against any of the following:
|
•
|
a breach of the duty of loyalty, except for indemnification and
insurance for a breach of the duty of loyalty to the company to the
extent that the office holder acted in good faith and had a
reasonable basis to believe that the act would not prejudice the
company;
|
|
•
|
a breach of duty of care committed intentionally or recklessly,
excluding a breach arising out of the negligent conduct of the
office holder;
|
|
•
|
an act or omission committed with intent to derive illegal personal
benefit; or
|
|
•
|
a fine, monetary sanction or forfeit levied against the office
holder.
|
Under the Israeli Companies Law,
exculpation, indemnification and insurance of office holders must
be approved by the compensation committee and the board of
directors and, with respect to directors or controlling
shareholders, their relatives and third parties in which
controlling shareholders have a personal interest, also by the
shareholders.
Our amended and restated articles of
association permit us to exculpate, indemnify and insure our office
holders to the fullest extent permitted or to be permitted by law.
Our office holders are currently covered by a directors’ and
officers’ liability insurance policy. As of the date of this annual
report, no claims for directors’ and officers’ liability insurance
have been filed under this policy and we are not aware of any
pending or threatened litigation or proceeding involving any of our
office holders, including our directors, in which indemnification
is sought.
We have entered into agreements with
each of our current office holders exculpating them from a breach
of their duty of care to us to the fullest extent permitted by law,
subject to limited exceptions, and undertaking to indemnify them to
the fullest extent permitted by law, subject to limited exceptions,
including to the extent that these liabilities are not covered by
insurance. This indemnification is limited, with respect to any
monetary liability imposed in favor of a third party, to events
determined as foreseeable by the board of directors based on our
activities. The maximum aggregate amount of indemnification that we
may pay to our office holders based on such indemnification
agreement is the greater of (i) 25% of our total shareholders’
equity pursuant to our most recent financial statements as of the
time of the actual payment of indemnification and (ii) $40.0
million (as may be increased from time to time by shareholders’
approval); provided, however, that in relation to indemnification
claimed in connection with a public offering of our securities, the
amount, if higher, shall be equal to the aggregate proceeds from
the sale by the Company and/or any shareholder of the Company in
connection with such public offering. Such indemnification amounts
are in addition to any insurance amounts. Each office holder who
agrees to receive this letter of indemnification also gives his
approval to the termination of all previous letters of
indemnification that we have provided to him or her in the past, if
any. However, in the opinion of the SEC, indemnification of office
holders for liabilities arising under the Securities Act is against
public policy and therefore unenforceable.
Employment and
Consulting Agreements with Executive Officers
We have entered into written
employment or service agreements with each of our executive
officers. See “Item 7.B. Related Party Transactions—Employment
Agreements.”
As of December 31, 2021, we had
542 employees, independent consultants and independent
contractors, of which 282 were in located in Israel, 159 were
located in the United States, 27 were located in the United Kingdom
and approximately 74 were located across 19 other countries. Set
forth below is a breakdown of our global workforce of employees,
independent consultants and independent contractors by category of
activity as of the dates indicated:
|
|
As of
December 31,
|
|
|
|
2019
|
|
|
2020
|
|
|
2021
|
|
Services,
support and fulfillment
|
|
|
98
|
|
|
|
97
|
|
|
|
100
|
|
Research and
development
|
|
|
187
|
|
|
|
177
|
|
|
|
171
|
|
Sales and
marketing
|
|
|
223
|
|
|
|
194
|
|
|
|
198
|
|
General and
administrative
|
|
|
60
|
|
|
|
65
|
|
|
|
73
|
|
Total
|
|
|
568
|
|
|
|
533
|
|
|
|
542
|
|
With respect to our Israeli
employees, Israeli labor laws govern the length of the workday,
minimum wages for employees, procedures for hiring and dismissing
employees, determination of severance pay, annual leave, sick days,
advance notice of termination of employment, equal opportunity and
anti-discrimination laws and other conditions of employment.
Subject to certain exceptions, Israeli law generally requires
severance pay upon the retirement, death or dismissal of an
employee, and requires us and our employees to make payments to the
National Insurance Institute, which is similar to the U.S. Social
Security Administration. Our Israeli employees have pension plans
that comply with the applicable Israeli legal requirements, and we
make monthly contributions to severance pay funds for all Israeli
employees, which cover potential severance pay obligations.
Extension orders issued by the
Israeli Ministry of Economy and Industry (formerly the Israeli
Ministry of Industry, Trade and Labor) apply to our employees in
Israel and affect matters such as, living adjustments to salaries,
length of working hours and week, recuperation pay, travel
expenses, and pension rights. We have never experienced
labor-related work stoppages or strikes and believe that our
relations with our employees are satisfactory.
For information regarding the share
ownership of our directors and executive officers, please refer to
“Item 6.B. Compensation” and “Item 7.A. Major Shareholders.”
ITEM
7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
The following table sets forth
information with respect to the beneficial ownership of our shares
as of February 23, 2022 by:
|
•
|
each person or entity known by us to own beneficially more than 5%
of our outstanding shares;
|
|
•
|
each of our directors and executive officers individually;
and
|
|
•
|
all of our directors and executive officers as a group.
|
The beneficial ownership of ordinary
shares is determined in accordance with the rules of the SEC and
generally includes any ordinary shares over which a person
exercises sole or shared voting or investment power, or the right
to receive the economic benefit of ownership. For purposes of the
table below, we deem shares subject to options or warrants that are
currently exercisable or exercisable within 60 days of February 23,
2022 to be outstanding and to be beneficially owned by the person
holding the options or warrants for the purposes of computing the
percentage ownership of that person but we do not treat them as
outstanding for the purpose of computing the percentage ownership
of any other person. The percentage of shares beneficially owned is
based on 37,921,019 ordinary shares outstanding as of February 23,
2022.
As of February 23, 2022, we had 5
holders of record of our ordinary shares in the United States,
including Cede & Co., the nominee of The Depository Trust
Company. These shareholders held an aggregate of 33,996,364, or
89.7%, of our ordinary shares outstanding as of February 23, 2022.
The number of record holders in the United States is not
representative of the number of beneficial holders nor is it
representative of where such beneficial holders are resident, since
many of these ordinary shares were held by brokers or other
nominees.
All of our shareholders, including
the shareholders listed below, have the same voting rights attached
to their ordinary shares. See “Item 10.B. Memorandum and Articles
of Association—Voting Rights and Conversion.” Unless otherwise
noted below, each shareholder’s address is Tufin Software
Technologies Ltd., 5 HaShalom Road, ToHa Tower, Tel Aviv 6789205,
Israel.
|
|
Shares
Beneficially Owned
|
|
Name of
Beneficial Owner
|
|
Number
|
|
|
%
|
|
Directors and Executive Officers
|
|
|
|
|
|
|
Reuven Kitov
(1)
|
|
|
1,971,853
|
|
|
|
5.2
|
%
|
Reuven
Harrison
|
|
|
1,736,191
|
|
|
|
4.6
|
%
|
Jack
Wakileh
|
|
|
*
|
|
|
|
*
|
|
Yoram
Gronich
|
|
|
*
|
|
|
|
*
|
|
Shay
Dayan
|
|
|
*
|
|
|
|
*
|
|
Raymond
Brancato
|
|
|
*
|
|
|
|
*
|
|
Ohad
Finkelstein (2)
|
|
|
500,280
|
|
|
|
1.3
|
%
|
Yuval Shachar
(3)
|
|
|
623,147
|
|
|
|
1.6
|
%
|
Yair
Shamir
|
|
|
*
|
|
|
|
*
|
|
Edouard
Cukierman
|
|
|
*
|
|
|
|
*
|
|
Peter
Campbell
|
|
|
*
|
|
|
|
*
|
|
Dafna
Gruber
|
|
|
*
|
|
|
|
*
|
|
Tom
Schodorf
|
|
|
*
|
|
|
|
*
|
|
Brian
Gumbel
|
|
|
*
|
|
|
|
*
|
|
All directors
and executive officers as a group (14 persons) (4)
|
|
|
|
|
|
|
12.0
|
%
|
Principal Shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ETF Managers
Group LLC (5)
|
|
|
2,745,165
|
|
|
|
7.2
|
%
|
|
|
|
|
|
|
|
|
|
EVR Research LP
(6)
|
|
|
2,360,000
|
|
|
|
6.1
|
%
|
_______________________
|
*
|
Less than
1%.
|
(1)
|
Includes
639,350 shares held in trust for family members over which Reuven
Kitov is the beneficial owner.
|
(2)
|
Includes
473,968 shares Ohad Finkelstein may be deemed to beneficially own
through entities affiliated with Marker LLC and 10,638 shares
issuable upon the exercise of options exercisable within 60 days of
February 23, 2022.
|
(3)
|
Includes
473,968 shares Yuval Shachar may be deemed to beneficially own
through entities affiliated with Marker LLC and 60,360 shares
issuable upon the exercise of options exercisable within 60 days of
February 23, 2022.
|
(4)
|
See notes 1
through 3 above. Includes 4,625,638 ordinary shares and 122,500
shares issuable upon the exercise of options exercisable within 60
days of February 23, 2022.
|
(5)
|
The information in the table above concerning the number of
shares beneficially owned by ETF Managers Group LLC, was obtained
from a Schedule 13G/A filed with the SEC by ETF Managers Group LLC
on December 22, 2021 reporting beneficial ownership at December 17,
2021. The address of the foregoing entity is ETF Managers Group
LLC, 30 Maple Street, Suite 2, Summit, NJ 07091.
|
(6) |
The information in the table above concerning the number of
ordinary shares beneficially owned by EVR Master Fund, LP was
obtained from a Schedule 13G/A filed with the SEC by EVR Research
LP and EVR Master Fund, LP on February 28, 2022 reporting
beneficial ownership as of such date, and includes 1,630,000
ordinary shares and call options exercisable into 730,000 ordinary
shares held by EVR Master Fund, LP. EVR Research LP, as the
investment manager of EVR Master Fund, LP and certain other funds,
may be deemed an indirect beneficial owner of the ordinary shares.
Benjamin Wolf Joffe is the managing member of the general partner
of EVR Research LP and exercises investment discretion with respect
to these ordinary shares held directly by EVR Master Fund, LP and
certain other funds. The address of EVR Research LP is 411 Libbie
Avenue, Suite 3, Richmond, VA 23226, and the address for EVR Master
Fund, LP is 411 Libbie Avenue, Suite 3, Richmond, VA 23226.
|
Changes
in Ownership
Immediately after our IPO, entities
affiliated with Catalyst Private Equity Partners (II), Limited
Partnership and Marker LLC owned approximately 19% and 21% of our
outstanding ordinary shares, respectively. As a result of various
sell-downs and distributions to their limited partners and members
over time, these entities decreased their ownership of our ordinary
shares, and eventually ceased to be 5% beneficial owners of our
outstanding ordinary shares in the fiscal year ended December 31,
2021.
|
|
B. |
Related Party Transactions
|
Our policy is to enter into
transactions with related parties on terms that, on the whole, are
no more favorable, or no less favorable, than those available from
unaffiliated third parties. Based on our experience in the business
sectors in which we operate and the terms of our transactions with
unaffiliated third parties, we believe that all of the transactions
described below met this policy standard at the time they occurred.
The following is a description of material transactions, or series
of related material transactions, since January 1, 2021, to which
we were or will be a party and are reportable as related party
transactions under Item 7.B of Form 20-F.
Agreements with
Related Parties
Registration Rights
Our amended and restated investors’
rights agreement entitles certain of our shareholders to certain
registration rights, including the following:
Form F-1 Demand Rights. The holders of
at least 25% of the shares held by our former preferred
shareholders can provide us a written request to file a
registration statement in respect of the ordinary shares issued
upon conversion of the preferred shares, or the “registrable
securities.” Within 10 days of the receipt of a request to effect
such registration, we must give written notice of the request to
the other holders of the registrable securities. We are not
required to effect more than two registrations on Form F-1 that
have been declared or ordered effective as promptly as practicable.
We are only required to effect any such registration if the
anticipated aggregate proceeds will be at least $5.0 million (net
of underwriting discounts).
Form F-3 Demand Rights. Upon the
written request of any former preferred shareholders that we effect
a registration on Form F-3, we must give written notice of the
proposed registration within 10 days, and any related qualification
or compliance, to all other former preferred shareholders. We must
use commercially reasonable efforts to effect such registration and
all such qualifications and compliances requested, together with
all or such portion of the registrable securities of any other
former preferred shareholders joining in such request. We are not
required to effect a registration on Form F-3 more than twice in
any 12-month period. We are only required to effect any such
registration if the anticipated aggregate proceeds will be at least
$1.0 million.
Shelf Takedown. Upon the written
request of any former preferred shareholders that we effect a
public offering using an effective shelf registration statement, we
must give written notice of the proposed offering within 10 days
(or two business days in connection with an underwritten “block
trade”), and any related qualification or compliance, to all other
former preferred shareholders. We are not required to effect an
underwritten shelf takedown if we effected a demand registration,
piggyback offering or underwritten shelf takedown within the
preceding 90 days. We are only required to effect an underwritten
shelf takedown if the anticipated aggregate proceeds will be at
least $5.0 million.
Piggyback Offerings. Shareholders
holding registrable securities have the right to request to
participate in any offering initiated by us, subject to specified
exceptions. Holders of registrable securities continue to have the
right to participate in subsequent piggyback offerings regardless
of whether the holder has opted out of prior offerings.
Cutback. In the event that the
underwriter advises us that marketing factors require a limitation
on the number of shares that can be included in a registered
offering, the shares will be included in the registration statement
in an agreed order of preference among the holders of registration
rights. The same preference also applies in the case of a piggyback
offering, but we have first preference and the amount of
registrable securities to be included may not be reduced below 25%
of the total amount of securities included in such offering.
Termination. Rights granted to holders
of registrable securities pursuant to the amended and restated
investors’ rights agreement terminate on the fifth anniversary of
the closing of our initial public offering. With respect to any of
our holders of registrable securities that hold less than 4% of our
outstanding ordinary shares, such rights terminate when the shares
held by such shareholder can be sold within a 90-day period under
Rule 144. We have the right to terminate or delay any registration
or offering, even if such registration or offering is subject to
piggyback rights.
Expenses. We will pay all expenses in
carrying out the foregoing registrations or offerings other than
any underwriting discounts.
Rights of
Appointment
Our current board of directors
consists of ten directors. Our founders, Reuven Kitov and Reuven
Harrison, have agreed that Reuven Kitov will designate the director
that our founders are permitted to jointly appoint under certain
circumstances for so long as our founders share such designation
right as set forth in our amended and restated articles of
association. See “Item 6.C. Board Practices—Appointment Rights.”
Otherwise, as of the date of this annual report, we are not a party
to, and are not aware of, any voting or board appointment
agreements among our shareholders.
Agreements with
Directors and Executive Officers
Employment Agreements. We have entered
into written employment agreements with each of our executive
officers. These agreements provide for notice periods of varying
duration for termination of the agreement by us or by the relevant
executive officer, during which time the executive officer will
continue to receive base salary and benefits. These agreements also
contain customary provisions regarding noncompetition,
confidentiality of information and assignment-of-inventions.
However, the enforceability of the noncompetition provisions may be
limited under applicable law.
Equity Awards. Since October 2007, we
have granted options to purchase our ordinary shares and Restricted
Stock Units (“RSUs”) to our officers and to our directors. Such
option agreements may contain acceleration provisions upon certain
merger, acquisition, or change of control transactions. We describe
our option plans under “Equity Incentive Plans” in this annual
report. If our relationship with an executive officer or a director
is terminated, except for cause (as defined in the various option
plan agreements), all options that are vested will remain
exercisable for 90 days after such termination (180 days in case of
death, retirement or disability) or until expiration of the term of
the option award, whichever is earlier.
The following table provides
information as of February 23, 2022, regarding the outstanding
unvested RSUs for our ordinary shares granted to our directors and
executive officers that, in each case, beneficially own 1% or more
of our ordinary shares:
Name/Title
|
|
Number of Shares Underlying RSUs
|
|
Reuven Kitov,
Chief Executive Officer, Chairman of the Board of Directors and
Co-Founder
|
|
|
187,500
|
|
Reuven
Harrison, Chief Technology Officer and Co-Founder
|
|
|
85,000
|
|
Exculpation, Indemnification and
Insurance. Our amended and restated articles of association
permit us to exculpate, indemnify and insure certain of our office
holders to the fullest extent permitted by the Israeli Companies
Law. We entered into agreements with our office holders,
exculpating them from a breach of their duty of care to us to the
fullest extent permitted by law and undertaking to indemnify them
to the fullest extent permitted by law, subject to certain
exceptions. See “Item 6.C. Board Practices—Exculpation, Insurance
and Indemnification of Directors and Officers.”
Directors’ Service Contracts. There are
no arrangements or understandings between us, on the one hand, and
any of our directors, on the other hand, providing for benefits
upon termination of their employment or service as directors of our
company.
|
C. |
Interests of Experts and
Counsel
|
Not applicable.
ITEM
8. FINANCIAL INFORMATION
|
A. |
Consolidated Statements and Other
Financial Information
|
Consolidated
Financial Statements
We have appended as part of this
annual report our consolidated financial statements starting at
page F-1.
Legal
Proceedings
From time to time, we may become
involved in legal proceedings or be subject to claims arising in
the ordinary course of its business. For more information on major
pending legal proceedings, see Note 14 to our consolidated
financial statements under “Legal Proceedings.”
Dividend
Policy
We have never declared or paid any
cash dividends on our ordinary shares. We do not anticipate paying
any cash dividends in the foreseeable future. We currently intend
to retain future earnings, if any, to finance operations and expand
our business. Our board of directors has sole discretion whether to
pay dividends. If our board of directors decides to pay dividends,
the form, frequency and amount will depend upon our future
operations and earnings, capital requirements and surplus, general
financial condition, contractual restrictions and other factors
that our directors may deem relevant. The distribution of dividends
may also be limited by Israeli law, which permits the distribution
of dividends only out of retained earnings or otherwise upon the
permission of an Israeli court.
B.
Significant Changes
No significant changes have occurred
since December 31, 2021, except as otherwise disclosed in this
annual report.
ITEM
9.THE OFFER AND LISTING
|
A. |
Offer and Listing Details
|
Our ordinary shares commenced
trading on NYSE on April 11, 2019. Prior to that date, no public
market existed for our ordinary shares.
Not applicable.
Our ordinary shares are listed and
traded on NYSE under the symbol “TUFN”.
Not applicable.
Not applicable.
Not applicable.
ITEM
10. ADDITIONAL INFORMATION
Not applicable.
|
B. |
Memorandum and Articles of
Association
|
A copy of our amended and restated
articles of association is attached as
Exhibit 1.1 to this annual report. The information called for
by this Item is set forth in
Exhibit 2.5 to this annual report and is incorporated by
reference into this annual report.
For a description of the
registration rights that we granted under our Fourth Amended
Investor Rights Agreement, please refer to “Item 7.B. Related Party
Transaction—Registration Rights.”
There are currently no Israeli
currency control restrictions on remittances of dividends on our
ordinary shares, proceeds from the sale of the shares or interest
or other payments to non-residents of Israel, except for
shareholders who are subjects of certain countries that are, or
have been, in a state of war with Israel at such time.
The following is a brief summary of
material Israeli income tax laws and government programs applicable
to us. Some parts of this discussion are based on new Israeli tax
legislation, which has not been subject to judicial or
administrative interpretation. The discussion is general in nature,
should not be construed as comprehensive legal or professional tax
advice and does not cover all possible tax considerations in
general and especially tax considerations that may be relevant to a
particular investor in light of his, her or its personal investment
circumstances or to some types of investors which are subject to
special treatment under Israeli tax law. You should consult your
own tax advisor concerning the tax consequences of your particular
situation, as well as any tax consequences that may arise under the
laws of any state, local, foreign or other taxing
jurisdiction.
Certain Israeli
Tax Consequences
General
Corporate Tax Structure in Israel
Israeli resident companies are
generally subject to corporate tax on their taxable income at the
rate of 23% for the year ended December 31, 2021 (in 2019 and 2020
the corporate tax rate was also 23%). However, the effective tax
rate payable by a company that derives income from an Approved
Enterprise, a Beneficiary Enterprise, a Preferred Enterprise, a
Special Preferred Enterprise, a Preferred Technology Enterprise or
Special Preferred Technology Enterprise (as defined below) may be
considerably less.
Capital gains derived by an Israeli
resident company are subject to tax at the corporate tax rate of
23%, as mentioned above. Under Israeli tax legislation, a
corporation will be considered as an “Israeli resident company” if
(i) it was incorporated in Israel or (ii) the control and
management of its business are exercised in Israel.
Law for
the Encouragement of Industry (Taxes), 5729-1969
The Law for the Encouragement of
Industry (Taxes), 5729-1969, generally referred to as the Industry
Encouragement Law, provides several tax benefits for “Industrial
Companies.”
The Industry Encouragement Law
defines an “Industrial Company” as a company, resident in Israel,
that was incorporated in Israel, which 90% or more of its income in
any tax year, other than income from defense loans, is derived from
an “Industrial Enterprise” owned by it and that is located in
Israel or in the “Area”, in accordance with the definition under
section 3A of the Israeli Tax Ordinance. An “Industrial Enterprise”
is defined as an enterprise whose principal activity in a given tax
year is industrial production.
The following corporate tax
benefits, among others, are available to Industrial
Companies:
|
•
|
amortization over an eight-year period of the cost of purchased
know-how and patents and rights to use a patent and know-how which
are used for the development or advancement of the Industrial
Enterprise, commencing on the year in which such rights were first
utilized;
|
|
•
|
under limited conditions, an election to file consolidated tax
returns with related Israeli Industrial Companies; and
|
|
•
|
expenses related to a public offering are deductible in equal
amounts over three years commencing on the year of the
offering.
|
Eligibility for benefits under the
Industry Encouragement Law is not subject to receipt of prior
approval from any governmental authority.
Although as of the date of this
annual report, we do not have industrial production activities, we
may qualify as an Industrial Company in the future and may be
eligible for the benefits described above.
Tax
Benefits and Grants for Research and Development
Israeli tax law allows, under
certain conditions, a tax deduction for expenditures related to
scientific research and development projects, including capital
expenditures, in the year in which they are incurred, if:
|
•
|
the expenditures are approved by the relevant Israeli government
ministry, determined by the field of research;
|
|
•
|
the research and development must be for the promotion or
development of the company; and
|
|
•
|
the research and development is carried out by or on behalf of the
company seeking such tax deduction.
|
The amount of such deductible
expenses is reduced by the sum of any funds received through
government grants for the financing of such scientific research and
development projects. No deduction under these research and
development deduction rules is allowed if such deduction is related
to an expense invested in an asset depreciable under the general
depreciation rules of the Israeli Tax Ordinance. Expenditures
related to research for the promotion or development of the company
not so approved, are deductible in equal amounts over three
years.
From time to time, we may apply to
the Innovation Authority for approval to allow a tax deduction for
all research and development expenses during the year incurred.
There can be no assurance that such application will be
accepted.
Law for
the Encouragement of Capital Investments, 5719-1959
The Law for the Encouragement of
Capital Investments, 5719-1959, generally referred to as the
Investment Law, provides certain incentives for enterprises
including in the cases of capital investments in production
facilities (or other eligible assets). Generally, an enterprises
that may be either an “Approved Enterprise”, a “Beneficiary
Enterprise”, a “Preferred Enterprise”, a “Special Preferred
Enterprise”, a “Preferred Technology Enterprise” or “Special
Preferred Technology Enterprise”, is entitled to benefits as
discussed below. These benefits may include cash grants from the
Israeli government and tax benefits, based upon, among other
things, the location within Israel of the facility in which the
investment and manufacture activity are made. In order to qualify
for these incentives, an Approved Enterprise, a Beneficiary
Enterprise or, a Preferred Enterprise, a Special Preferred
Enterprise, a Preferred Technology Enterprise or Special Preferred
Technology Enterprise, is required to comply with the requirements
of the Investment Law.
The Investment Law has been amended
several times over the recent years, with the three most
significant changes effective as of April 1, 2005, referred to as
the 2005 Amendment, as of January 1, 2011, referred to as the 2011
Amendment, and as of January 1, 2017, referred to as 2017
Amendment. Pursuant to the 2005 Amendment, tax benefits granted in
accordance with the provisions of the Investment Law prior to its
revision by the 2005 Amendment remain in force, but any benefits
granted subsequently are subject to the provisions of the amended
Investment Law. Similarly, the 2011 Amendment introduced new
benefits instead of the benefits granted in accordance with the
provisions of the Investment Law prior to the 2011 Amendment, yet
companies entitled to benefits under the Investment Law as in
effect up to January 1, 2011, were entitled to choose to continue
to enjoy such benefits, provided that certain conditions are met,
or elect instead, irrevocably, to forego such benefits and elect
for the benefits of the 2011 Amendment. The 2017 Amendment
introduced new benefits for Technological Enterprises, alongside
the existing tax benefits.
Tax
Benefits Prior to the 2005 Amendment
An investment program that is
implemented in accordance with the provisions of the Investment Law
prior to the 2005 Amendment, referred to as an “Approved
Enterprise”, is entitled to certain benefits. A company that wished
to receive benefits as an Approved Enterprise must have received
approval from the Investment Center of the Israeli Ministry of
Economy and Industry, referred to as the Investment Center. Each
certificate of approval for an Approved Enterprise relates to a
specific investment program in the Approved Enterprise, delineated
both by the financial scope of the investment and by the physical
characteristics of the facility or the asset.
In general, an Approved Enterprise
was entitled to receive a grant from the Israeli government under
the “Grant Track” or an alternative package of tax benefits, known
as the “Alternative Track”. The tax benefits from any certificate
of approval relate only to taxable profits attributable to the
specific Approved Enterprise and are contingent upon meeting the
criteria set out in the certificate of approval. Income derived
from activity that is not integral to the activity of the Approved
Enterprise does not qualify for the tax benefits.
In addition, a company that has an
Approved Enterprise program is eligible for further tax benefits if
it qualifies as a Foreign Investors’ Company, or a FIC, which is a
company with a level of foreign investment, as defined in the
Investment Law, of more than 25%. The level of foreign investment
is measured as the percentage of rights in the company (in terms of
shares, rights to profits, voting and appointment of directors),
and of combined share and loan capital, that are owned, directly or
indirectly, by persons who are not residents of Israel. The
determination as to whether a company qualifies as an FIC is made
on an annual basis according to the lowest level of foreign
investment during the year.
We are currently not entitled to tax
benefits for Approved Enterprise.
Tax
Benefits Subsequent to the 2005 Amendment
The 2005 Amendment applies to new
investment programs commencing after 2004, but does not apply to
investment programs approved prior to April 1, 2005. The 2005
Amendment provides that terms and benefits included in any
certificate of approval that was granted before the 2005 Amendment
became effective on April 1, 2005 will remain subject to the
provisions of the Investment Law as in effect on the date of such
approval. Pursuant to the 2005 Amendment, the Investment Center
will continue to grant Approved Enterprise status to qualifying
investments. The 2005 Amendment, however, limits the scope of
enterprises that may be approved by the Investment Center by
setting criteria for the approval of a facility as an Approved
Enterprise, such as provisions generally requiring that at least
25% of the Approved Enterprise’s income be derived from
exports.
An enterprise that qualifies under
these provisions is referred to as a “Beneficiary Enterprise”,
rather than “Approved Enterprise”. The 2005 Amendment provides that
the Investment Center’s approval is required only for Approved
Enterprise that receive cash grants. As a result, it was no longer
required to obtain Approved Enterprise status in order to receive
the tax benefits previously available under the Alternative Track.
Rather, a company may claim the tax benefits offered by the
Investment Law directly in its tax returns, provided that its
facilities meet the criteria for tax benefits set forth in the 2005
Amendment. Companies are entitled to approach the Israeli Tax
Authority for a pre-ruling regarding their eligibility for benefits
under the Investment Law, as amended.
In order to receive the tax
benefits, the 2005 Amendment states that a company must make an
investment which meets all of the conditions, including exceeding a
minimum investment amount specified in the Investment Law. Such
investment allows a company to receive “Beneficiary Enterprise”
status, and may be made over a period of no more than three years
ending in the year in which the company chose to have the tax
benefits apply to its Beneficiary Enterprise (the “Year of
Election”).
Where a company requests to apply
the tax benefits to an expansion of existing facilities, only the
expansion will be considered to be a Beneficiary Enterprise and the
company’s effective tax rate will be the weighted average of the
applicable rates. In this case, the minimum investment required in
order to qualify as a Beneficiary Enterprise is required to exceed
a certain percentage of the value of the company’s production
assets before the expansion.
The benefits period is subject to a
limitation of 7 to 10 years from the Commencement Year (the
Commencement Year being defined as the later of: (i) the first tax
year in which the company derives income for tax purposes from the
Beneficiary Enterprise or (ii) the Year of Election) provided that
12 years have not elapsed from the first day of the Year of
Election.
The extent of the tax benefits
available under the 2005 Amendment to qualifying income of a
Beneficiary Enterprise depend on, among other things, the
geographic location in Israel of the Beneficiary Enterprise. Such
tax benefits include an exemption from corporate tax on
undistributed income for a period of between two to 10 years,
depending on the geographic location of the Beneficiary Enterprise
in Israel, and a reduced corporate tax rate of between 10% to 25%
for the remainder of the benefits period, depending on the level of
foreign investment in the company in each year. A company
qualifying for tax benefits under the 2005 Amendment which pays a
dividend out of income derived by its Beneficiary Enterprise during
the tax exemption period, will be subject to corporate tax in
respect of the amount of the dividend distributed (grossed-up to
reflect the pre-tax income that it would have had to earn in order
to distribute the dividend) at the otherwise applicable corporate
tax rate (while taking into account the entitlement for reduced
rates under the Investment Law . Dividends paid to Israeli
shareholders out of income attributed to a Beneficiary Enterprise
are generally subject to withholding tax at source at the rate of
15% (in the case of non-Israeli shareholders - subject to the
receipt in advance of a valid certificate from the ITA allowing for
a reduced tax rate, 15%, or or such lower rate as may be provided
in an applicable tax treaty (subject to the receipt in advance of a
valid certificate from the Israel Tax Authority allowing for a
reduced tax rate). The reduced rate of 15% is limited to dividends
and distributions out of income attributed to a Beneficiary
Enterprise during the benefits period and which are actually paid
at any time up to 12 years thereafter (except with respect to an
FIC, in which case the 12-year limit does not apply).
The benefits available to a
Beneficiary Enterprise are subject to the fulfillment of conditions
stipulated in the Investment Law and its regulations. If a company
does not meet these conditions, it may be required to refund the
amount of tax benefits, as adjusted by the Israeli consumer price
index, and interest, or other monetary penalties.
We applied for tax benefits as a
Beneficiary Enterprise with 2009 and 2011 as the Years of Election.
We may be entitled to tax benefits under this regime in respect of
the 2011 Year of Election once we are profitable for tax purposes
and subject to the fulfillment of all the relevant conditions. If
we do not meet these conditions, the tax benefits may not be
applicable which would result in adverse tax consequences to us.
Alternatively, and subject to the fulfillment of all the relevant
conditions, we may elect in the future to irrevocably waive the tax
benefits available for Beneficiary Enterprise and claim the tax
benefits available to Preferred Enterprise under the 2011 Amendment
(as defined below).
Tax
Benefits Under the 2011 Amendment
The Investment Law was significantly
amended as of January 1, 2011. The 2011 Amendment introduced new
benefits to replace those granted in accordance with the provisions
of the Investment Law in effect prior to the 2011 Amendment.
The 2011 Amendment introduced new
tax benefits for income generated by a “Preferred Company” through
its “Preferred Enterprise,” in accordance with the definition of
such term in the Investment Law, as of January 1, 2011. A Preferred
Company is defined as either (i) a company incorporated in Israel
which is not wholly owned by a governmental entity, or (ii) a
limited partnership that: (a) was registered under the Israeli
Partnerships Ordinance and; (b) all of its limited partners are
companies incorporated in Israel, but not all of them are
governmental entities; which has, among other things, Preferred
Enterprise status and is controlled and managed from Israel.
Since 2017 and thereafter, the
corporate tax rate for Preferred Enterprise, which is located in
development zone A, was decreased to 7.5%, while the reduced
corporate tax rate for other development zones remains 16%. Income
derived by a Preferred Company from a “Special Preferred
Enterprise”, as such term is defined in the Investment Law, would
be entitled, during a benefits period of 10 years, to further
reduced tax rates of 8%, or to 5% if the Special Preferred
Enterprise is located in development zone A. Our operations are
currently not located in development zone A.
Dividends paid to Israeli
shareholders out of income attributed to a Preferred Enterprise are
generally subject to withholding tax at source at the rate of 20%
(in the case of non-Israeli shareholders - subject to the receipt
in advance of a valid certificate from the ITA allowing for a
reduced tax rate, 20%), or such lower rate as may be provided in an
applicable tax treaty. However, if such dividends are paid to an
Israeli company, no tax is required to be withheld (although, if
such dividends are subsequently distributed to individuals or a
non-Israeli company, the aforesaid will apply).
We are currently not entitled to tax
benefits for a Preferred Enterprise or Special Preferred
Enterprise.